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Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder. The earliest and 
most severe neuropathological change in HD occurs within the striatum. Exogenous excitotoxic 
lesioning of the rodent and non-human primate (NHP) striatum is used to model HD. Apart from 
NHPs, no other excitotoxic large animal model of HD has been established. Sheep have the potential 
to be an important species for modelling neurodegenerative disease, primarily because of 
neuroanatomical similarities between the sheep and human brain. This thesis describes the 
development of an excitotoxic sheep model of HD using the excitotoxin, quinolinic acid (QA). QA is an 
N-methyl-D-aspartate (NMDA) glutamate receptor agonist that produces pathological changes within 
the striatum that resemble those seen in HD.  
Sixteen castrated-male, 18 month old, Merino-Border Leicester cross sheep underwent two 
surgical procedures, four weeks apart, to infuse 75 µl of 180 mM QA (experimental group) or 75 µl of 
saline (control group) into the left (first surgery) and then the right (second surgery) caudate nucleus 
of the striatum. Longitudinal magnetic resonance imaging (MRI), magnetic resonance spectroscopy 
(MRS) and diffusion tensor imaging (DTI) of the brains of the sheep was performed on a 3-Tesla 
scanner pre-surgically, one week after the first surgery, five weeks after the first surgery and sixteen 
weeks after the first surgery to investigate the neuropathological changes that occur in vivo after QA 
lesioning of the sheep striatum. The phenotypic consequences of lesioning the sheep striatum with 
QA were investigated using a veterinary neurological examination, dopamine agonist induced 
rotation and a two-choice discrimination task. The author / investigator was blind to the treatment 
group. 
MRI revealed QA-lesion hyperintensity and dilation of the lateral ventricles, consistent with 
atrophy of the caudate nucleus. MRS and DTI revealed a significant decrease in the neuronal marker 




surgery) striatae of the QA-lesioned sheep, followed by recovery in NAA and a significant increase in 
FA in the chronic (five to sixteen weeks) QA-lesioned striatae. NAA and FA changes are consistent 
with neuronal loss and structural disruption in the acute lesion, followed by recovery of reversibly 
impaired neurons, structural reorganisation and gliosis in the chronic lesion. Heterogeneous neuronal 
loss and damage and gliosis were visible on histological analysis of the QA-lesioned sheep striatae, 
supporting the in vivo MRS and DTI detected changes.  
Neurological examination of the sheep revealed evidence of laterality and mild hind limb motor 
paresis in seven out of eight of the QA-lesioned sheep, however the examination was not informative 
of lesion characteristics. A directional bias was evident in the QA-lesioned sheep during rotation 
studies. However, the direction and magnitude of bias in individual sheep at any one timepoint varied 
markedly, making identification of QA-lesioned individuals difficult. There was no difference between 
the QA-lesioned and saline-treated sheep in performance of the acquisition and reversal phases of 
the two-choice discrimination task. The behavioural studies described in this thesis were not suitable 
for comprehensive identification and characterisation of QA lesions in the striatum of sheep. 
This is the first description of the development of an acute excitotoxic sheep model of HD. The 
experiments demonstrate that longitudinal analysis of the neuropathological changes in the QA-
lesioned sheep striatum is possible using advanced magnetic resonance modalities performed on a 
clinically relevant 3-Tesla scanner and that neuropathological changes are consistent with HD-like 
pathology in other species. Furthermore, phenotypic investigation of the QA-lesioned sheep is 
possible, however more refined methods than those described need to be utilised. The excitotoxic 










Only abbreviations that appear more than once and within the body of the text are shown. 
Abbreviations within figures or tables are explained in the corresponding legends. 
3-NP   3-nitropropionic acid 
CAG   cytosine-adenine-guanine  
CSF   cerebrospinal fluid 
CED   convection-enhanced delivery 
D1   dopamine receptor D1  
D2   dopamine receptor D2 
DTI   diffusor tensor imaging 
EEG   electroencephalography  
FA   fractional anisotropy 
GABA   gamma-aminobutyric acid 
GFAP   glial fibrillary acidic protein 
Gln   glutamine  
Glu   glutamate  
HD   Huntington’s disease 
HTT   Huntingtin gene 
HTT   Huntingtin protein 
Iba1   ionised calcium binding adaptor molecule 1 
Ins   myo-inositol  
mHTT   mutant Huntingtin protein 
MR   magnetic resonance 
MRI   magnetic resonance imaging 
MRS    magnetic resonance spectroscopy 
MSN / MSNs  medium spiny neuron(s) 
NAA   N-acetylaspartate 
NADPH   nicotinamide adenine dinucleotide phosphate 
NDS   normal donkey serum  




PBS   phosphate buffered saline 
PD   Parkinson’s disease 
QA   quinolinic acid 
S+    positively associated novel stimuli 
S-   negatively associated novel stimuli 
T1-MPRAGE  T1-weighted, magnetisation-prepared, rapid gradient-echo 
TE   echo time 
TNAA   N-acetylaspartate and N-acetylaspartylglutamate  














Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder caused by a 
polymorphic trinucleotide repeat within the Huntingtin gene (HTT) gene that codes for the 
Huntingtin protein (HTT). The disease causing gene has an abnormally long cytosine-adenine-guanine 
repeat (CAG)n encoding a polyglutamine tract near the N-terminus of the HTT protein, termed 
mutant huntingtin protein (mHTT; MacDonald et al. 1993). The CAG repeat is unstable during DNA 
replication and shows genetic anticipation (Zuhlke et al. 1993, Wheeler et al. 2007, Neto et al. 2017). 
The length of the repeat correlates inversely with age of onset, with longer CAG repeats predisposing 
individuals to an earlier age of onset (Wexler et al. 2004, Lee et al. 2012, Lee et al. 2015a). HD is 
always fatal, with an average of ten to twenty years from onset of clinical symptoms until death 
(Roos 2010). 
HD has a prodromal phase of up to fifteen years before clinical diagnosis. The prodromal phase is 
characterized by subtle motor, cognitive and behavioural changes (Stout et al. 2011, Mason and 
Barker 2015). HD was previously known as Huntington’s chorea due to the presence of an often 
dramatic chorea, a form of dyskinesia that results in irregular, involuntary movements 
(Bhattacharyya 2016). However, the symptomatic profile of patients is variable, with a broad range 
of intellectual, emotional, behavioural and physical changes, including (but not limited to) 
involuntary movements, speech and swallowing difficulties, reduced mental concentration, difficulty 
learning or planning, deteriorating ability to communicate, apathy, anxiety, irritability and depression 
(Ha and Fung 2012, Ghosh and Tabrizi 2018). Currently, there is no cure or disease-modifying therapy 





HD primarily leads to degeneration of the striatum, although a wide range of central nervous 
system and peripheral tissues are affected (Marques and Humbert 2013, Bates et al. 2015, Rub et al. 
2016). Because the striatum is the first region to degenerate in HD, HD research has greatly benefited 
our knowledge of the functional anatomy and pathology of this structure. Most pre-clinical studies 
on HD and other neurodegenerative diseases utilise rodent models (Dawson et al. 2018, Fisher and 
Bannerman 2019). Our knowledge of the striatum in other species is limited, and often relies on 
extrapolation of knowledge from rodent studies.  
The sheep has been proposed as a suitable animal model for HD therapeutic research in a 
translational capacity between rodent HD models and clinical trials (Morton and Howland 2013). A 
transgenic sheep model of HD exists (Jacobsen et al. 2010), however it has not developed the full 
spectrum of neuropathology associated with HD (Morton 2018), a problem that also occurs with 
transgenic rodent models (Yan et al. 2019). Because of the limited neuropathology that develops in 
transgenic HD models, excitotoxic lesioning of the striatum is frequently used in HD research to 
recreate the spectrum of striatal neuropathology associated with HD (Cui et al. 2018, Foucault-
Fruchard et al. 2018, Sánchez et al. 2018, Sumathi et al. 2018, Verma et al. 2018, Emerich et al. 2019, 
Lavisse et al. 2019). 
Excitotoxins are conformationally restricted analogues of the excitatory amino acid 
neurotransmitter, glutamate (Schliebs et al. 1996). Very recently, a non-human primate (NHP) 
excitotoxic HD model was developed for use in a translational capacity between rodent excitotoxic 
models and clinical trials (Lavisse, Williams et al. 2019), an indication of the continued relevance of 
the model. Aside from NHP models (for examples see: Burns et al. 1995, Kendall et al. 2000, Roitberg 
et al. 2002), no large animal excitotoxic model of HD has been developed.  
This study aimed, for the first time, to lesion the striatum of sheep with the excitotoxin quinolinic 
acid (QA) and examine the QA-lesioned sheep for a phenotype. Magnetic resonance studies were 




validate, in a large-brained animal, results from pre-clinical trials that utilise rodent excitotoxic 
models. It would also complement the transgenic sheep HD model, improve our knowledge of the 
role of the striatum in sheep and provide evidence for the suitability of sheep as a model of 
neurodegenerative disease. 
1.2 The striatum 
Placing an excitotoxic lesion directly within the sheep striatum and understanding the consequences 
and relationship to HD, requires knowledge of the normal striatum. The striatum is part a group of 
interconnected subcortical nuclei that form the basal ganglia (Lanciego et al. 2012). Traditionally the 
striatum was considered to be involved solely in control of motor function (Dudman and Krakauer 
2016), a view that arose because of the prominent motor symptoms of basal ganglia disorders like 
HD (Bates et al. 2015) and Parkinson’s disease (PD; Kalia and Lang 2015). Over time, our knowledge 
of the role of the striatum has been expanded to recognize the striatum’s importance in assimilating 
cognitive, emotive and motor input and monitoring and refining pre-selected actions, therefore 
having an important role in a diverse range of functions including planning, motivation, action-
selection, skill learning, habit formation, reward and modulation of motor behaviour (Burton et al. 
2015, Graybiel and Grafton 2015, Provost et al. 2015, Knowlton and Patterson 2018, Le Heron et al. 
2018, Robbe 2018). The striatum has an outwardly homogenous appearance that belies a 
complicated circuitry, which has made determining and understanding its many functions difficult 
(Benarroch 2016, Yin 2016, Gahm and Shi 2017).  
1.2.1 The gross anatomy of the striatum 
No study has been published that comprehensively compares the gross anatomy of the rodent, 
primate and sheep striatum. However, the gross anatomy, cellular morphology and neurochemical 
expression of one region of the ovine basal ganglia that is closely connected to the striatum, the 
substantia nigra, has been demonstrated to be very similar to the human brain (Murray et al. 2019). 




separate structures, the caudate nucleus and putamen, unlike in rodents (Lanciego and Vázquez 
2012, Ella et al. 2017, Dong 2019, Johnson et al. 2019, Sudheimer et al. 2019). Articles outlining 
major differences between the rodent brain and the large animal brain, as well as the anatomical 
similarities of the primate (including human), sheep and pig brain are available (Morton and Howland 
2013, John et al. 2017, McBride and Morton 2018, Morton 2018, Vink 2018, Murray et al. 2019), with 
the similarity between the human and sheep brain being important for the development of an 
excitotoxic sheep model of HD. Major similarities and differences are outlined in Sections 1.4.1 and 
1.4.2.  
The striatum is traditionally divided into two regions, the dorsal and the ventral striatum (Burke et 
al. 2017). The dorsal striatum is typically referred to as the striatum (corpus striatum or neostriatum; 
Snell 2010). The dorsal striatum, referred to hereafter as the striatum, is comprised of two sub-
cortical nuclei within the basal ganglia of the telencephalon; 1) the caudate nucleus and 2) the 
putamen (see Fig. 1.1).   
In primates (including humans) and sheep, the caudate nucleus is an elongated comma-shaped 
structure sitting dorsomedial to the larger, ovoid-shaped putamen (Lanciego and Vázquez 2012, 
Roshchupkin et al. 2016, Ella et al. 2017, Sudheimer et al. 2019). The caudate nucleus has a large 
head that extends ventrally and progressively narrows in an elongated posterior direction until only a 
thin tail remains, again extending ventrally (Snell 2010, Johns 2014). The putamen forms a concave 
ovoid shape intimately and medially bordered by the pallidium (internal and external globus pallidus; 
Ella et al. 2017, Tang et al. 2018b). The caudate nucleus sits directly beneath the lateral ventricle such 
that it forms the floor of the lateral ventricle (Snell 2010, Tang et al. 2018a). In effect the putamen 
sits within the crook of the caudate nucleus, the two structures being separated, in primates 
(Lanciego and Vázquez 2012, Sudheimer et al. 2019) and sheep (Ella et al. 2017), by a thick band of 
white matter that forms part of the internal capsule (Gerfen and Bolam 2016). Multiple thin bridges 






















Figure 1.1 Selected coronal sections of the sheep brain showing the gross anatomical features of the 
striatum at three locations; A) the ventral striatum, B) the head of the caudate nucleus and C) the tail 
























Whilst the caudate nucleus and putamen are two separate structures, functionally they are 
considered to be a single unit divided by the internal capsule (Gerfen 1992, Shipp 2016). In rodents, 
the caudate nucleus and putamen are not distinguishable and are commonly referred to as the 
caudoputamen (Swanson 2018), a key anatomical difference between rodents and humans. The 
ventral striatum sits below the striatum and comprises the nucleus accumbens and olfactory 
tubercule (Burke et al. 2017). 
1.2.2 The functional anatomy of the striatum 
The striatum integrates inputs from, and projects to, many brain regions (Lanciego et al. 2012). In 
this section of the introduction, an overview of the functional anatomy is given, however it focuses 
on areas important to QA and HD (QA creates changes within the striatum that resemble HD, 
discussed in Section 1.4.4) to maintain relevance. The striatum is the primary afferent structure of 
the basal ganglia (Gerfen 1984, Donoghue and Herkenham 1986, Guo et al. 2015). The striatum 
receives excitatory inputs from all regions of the cortex, ventral tegmental area and substantia nigra 
pars compacta and projects inhibitory inputs to the rest of the basal ganglia (Lanciego et al. 2012, 
Ogawa et al. 2018). Afferent striatal inputs from the cortex can be topographically mapped 
prescribing a regionality to the striatum, with the caudate nucleus associated with cognitive inputs 
and the putamen with motor control (Adler et al. 2013, Haber 2016). Because the caudate nucleus is 
associated with cognition, a two-choice discrimination task was established (see Chapter 4) to 
determine whether cognitive decline is identifiable in the QA-lesioned sheep. 
The striatum consists primarily of inhibitory gamma-aminobutyric acid (GABA) producing 
(Gonzales et al. 2013) medium sized spiny projection neurons (MSNs; Kita and Kitai 1988, Matamales 
et al. 2009). The MSNs can be further subdivided by receptor and neuropeptide expression such that 
two major subtypes of MSN exist (Grillner and Robertson 2016). The two major subtypes of MSN are 
defined by whether they contain D1 or D2 dopamine receptors (Perez et al. 2017, Yapo et al. 2017), 




Within the striatum is a small heterogeneous population of aspiny interneurons that form 
functional networks with, and modulate, MSN activity (Abudukeyoumu et al. 2018, Aldrin-Kirk et al. 
2018, Tepper et al. 2018). The exact proportion of MSNs and interneurons within the striatum vary 
between species (Graveland and DiFiglia 1985, Wu and Parent 2000). The majority of these 
interneurons are GABAergic and the different populations can be differentiated by the calcium-
binding proteins, paravalbumin and calretinin (Prensa et al. 1998, Wu and Parent 2000, Garas et al. 
2018). As well as the GABAergic interneurons, there are also large cholinergic interneurons (Klug et 
al. 2018) and interneurons that contain neuropeptide Y, somatostatin, nitric oxide synthase and 
nicotinamide adenine dinucleotide phosphate (NADPH) diaphorase (Waldvogel et al. 2015).  
Originating in the striatum and continuing throughout the basal ganglia are two structurally and 
functionally connected pathways, known as the indirect and direct pathways (Fig. 1.2; Cui et al. 2013, 
Calabresi et al. 2014, Nonomura et al. 2018, Tinterri et al. 2018). The direct and indirect pathways are 
simultaneously activated GABAergic MSN inhibitory pathways (Cui et al. 2013), however the direct 
pathway is functionally facilitatory in nature and the indirect pathway is functionally inhibitory 
(Lanciego et al. 2012, Nelson and Kreitzer 2014, Bahuguna et al. 2018). The direct pathway is mainly 
comprised of D1, substance P-expressing MSNs, while the indirect pathway is mainly comprised of 




























Figure 1.2 Classic projection neuron pathways within the basal ganglia (with thalamus and cerebral 
cortex). Excitatory pathways in red, inhibitory pathways in blue, dopamine pathway in green. 
Thalamus activation facilitates movement. Indirect pathway activation is associated with increased 
inhibition of the thalamus therefore inhibiting movement, direct pathway activation is associated 
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As well as direct and indirect pathway organization, the striatum also has a histochemically 
distinct striosome and matrix compartmental organization based on differential immunoreactivity 
and protein expression (Olson et al. 1972, Pert et al. 1976, Graybiel and Ragsdale 1978, Graybiel et al. 
1981, Herkenham and Pert 1981, Gerfen 1984, Gerfen et al. 1985). Striosomes form a labyrinth or 
patchwork like structure within the surrounding matrix (Brimblecombe and Cragg 2017). The output 
projections of the striosome and matrix differ and the pathway specificity of striosome and matrix 
projections may vary between species (Gerfen 1984, Levesque and Parent 2005, Watabe-Uchida et 
al. 2012, Crittenden et al. 2016, Reiner and Deng 2018, Fujiyama et al. 2019).  
Sensory cortical and limbic structures have also been shown to preferentially target direct 
pathway neurons and striosomes, while the motor cortex preferentially targets indirect pathway 
neurons and the matrix (Kincaid and Wilson 1996, Crittenden and Graybiel 2011, Wall et al. 2013). 
The striatum can be further arranged into a large number of functional and structural subdivisions, 
functionally connected to cerebrocortical functional networks (Ogawa et al. 2018). The regions and 
functional subdivisions within the striatum do not form exclusive boundaries, with substantial 
overlapping of the inputs and divisions associated with the integrative role of the basal ganglia 
(Mailly et al. 2013, Florio et al. 2018). 
1.2.3 The role of the wild-type huntingtin protein 
HTT is expressed throughout the nervous system and many tissues of the body (Li et al. 1993, Strong 
et al. 1993, Carroll et al. 2015). Even though there is almost ubiquitous expression of HTT, the specific 
functions of the protein are still not fully known (Liu and Zeitlin 2017, Selvaraj et al. 2020). HTT has 
been implicated in multiple processes, including; vesicle transport (Colin et al. 2008, Zala et al. 2013), 
ciliogenesis regulation (Keryer et al. 2011), endocytosis (Waelter et al. 2001), autophagy (Martin et 
al. 2015), steroidogenesis (Selvaraj et al. 2020) and transcription regulation (Valor 2015). HTT 
expression is present early in embryonic development, and disruption of the HTT gene is lethal if it 




of HTT in the adult is less clear. Disruption of HTT in the nervous system of adults may lead to 
selective neurodegeneration, with the striatum being particularly vulnerable (Dragatsis et al. 2000), 
however it has also been shown that neurodegeneration does not occur in adult mice for at least 
seven months after inactivation of HTT (Wang et al. 2016, Liu and Zeitlin 2017). 
1.3 Neuropathology of Huntington’s disease 
The pathophysiology of HD is complex and affects many areas of the brain and body outside of the 
striatum. In this section, an overview of HD neuropathology is given with a focus on striatal 
neuropathology that is relevant to a QA model of HD. 
HD is caused by an abnormal HTT protein, mHTT. HD results in widespread atrophy of the brain 
with reduced brain volume, cortical thinning and ventricular enlargement (de la Monte et al. 1988, 
Mason et al. 2018, Nanetti et al. 2018, Wijeratne et al. 2018). Particular regions of the brain affected 
in HD include the cerebral cortex, striatum, pallidum, thalamus, brainstem and cerebellum (Rub et al. 
2016).  
The earliest and most severe neuropathological changes in HD occur within the striatum 
(Vonsattel et al. 1985). Striatal neuronal loss and reactive gliosis follow a topographic distribution 
and ordered pattern, with the earliest recognisable changes occurring caudo-dorsally (primarily in 
the tail of the caudate nucleus and dorsal putamen) before progressively becoming more diffuse 
throughout the striatum. Severe atrophy of the striatum with concomitant concavity of the 
ventricular border and enlargement of the ventricle, eventually occurs due to significant neuronal 
loss (Fig. 1.3; Vonsattel et al. 1985, Waldvogel et al. 2015, Rub et al. 2016). Atrophy is visible in the 
caudate nucleus before the putamen (Reiner et al. 2011), which influenced the decision to target the 




Figure 1.3 Gross striatal pathology in the brain of a human with Huntington’s disease. Coronal 
sections at the level of the striatum of A) a 35 year old male brain without Huntington’s disease, and 
B) a grade 3/4 Huntington’s disease case. Arrows in (B) indicate severe atrophy of the striatum in the 
Huntington’s disease case. The lateral ventricle, which is the space the arrows have been drawn in, is 
visibly dilated due to the striatal atrophy. There is also atrophy of the cortex. CN = caudate nucleus, P 
= putamen. Image edited from Figure 2 of the Neuropathology of Huntington’s disease (2015) 













Atrophy of the striatum with concomitant lateral ventricle enlargement, evidence of 
corticostriatal projection neuron degeneration and evidence of other brain pathology is detectable in 
HD patients up to ten years before the onset of clinically observable symptoms (Tabrizi et al. 2013). 
The integrative role of the striatum with extensive motor, sensory, emotive and cognitive inputs 
suggests that pathology of this structure will have a broad clinical symptomology (Florio et al. 2018). 
As the disease progresses, a heterogeneous pattern of neurodegeneration eventually occurs 
throughout the basal ganglia and cerebral cortex. The heterogeneous neurodegeneration results in 
the variable symptomology of HD (Waldvogel et al. 2012a, Waldvogel et al. 2012b, Nana et al. 2014). 
For example, HD patients with significant striosome loss and preservation of the matrix showed 
predominantly mood symptoms, while HD patients with primarily matrix loss have a predominance 
of motor abnormalities (Tippett et al. 2007, Thu et al. 2010).  
In HD, widespread pathology eventually occurs in both neural and non-neural tissues (van der 
Burg et al. 2009, Mielcarek 2015, Rub et al. 2016). The pathological change in non-neural tissues is 
possibly due to a direct effect of mHTT expression in the tissue affected, as well as an indirect effect 
of neurodegeneration (van der Burg et al. 2009). The majority of HD patients die of pneumonia, 
possibly due to dysphagia-associated aspiration (Heemskerk and Roos 2012). Other prominent 
causes of death include infection, heart failure or suicide (Heemskerk and Roos 2010, Heemskerk and 
Roos 2012, Rodrigues et al. 2017). 
1.3.1 The role of the mutant-huntingtin protein in neuron cell death 
The relationship between mHTT and clinical disease is not yet understood. The CAG repeat causes a 
polyglutamine expansion that results in instability and misfolding of mHTT (MacDonald et al. 1993, 
Labbadia and Morimoto 2013). The misfolded protein forms characteristic aggregates and nuclear 
inclusions (Davies et al. 1997, DiFiglia et al. 1997). The role of the aggregates in the mechanism of 
disease is not fully appreciated (Waldvogel et al. 2015, Sahoo et al. 2016) though compromising the 




Even though a single mutant gene causes HD, the aetiology is complex (Bates et al. 2015). The HTT 
gene interacts with many other genes (Hodges et al. 2006, Dong and Cong 2018) resulting in 
dysfunction in multiple cellular processes (Waldvogel et al. 2015, Patassini et al. 2016), including; 
transcriptional dysregulation (Sharma and Taliyan 2015, Le Gras et al. 2017, Joag et al. 2019), axonal 
transport alterations (Reddy and Shirendeb 2012, Zhao et al. 2016), intracellular signalling defects 
(Trager et al. 2014), deregulation of the proteasome pathway (Liebelt and Vertegaal 2016, Lin et al. 
2016), autophagy (Ashkenazi et al. 2017), loss of calcium homeostasis and excitotoxicity 
(Bezprozvanny 2007, Glaser et al. 2018), alteration in brain cholesterol homeostasis (Di Pardo et al. 
2019) and mitochondrial dysfunction with resultant oxidative stress (Di Cristo et al. 2018). The 
expression of mHTT leads to disruption of central pathways of energy metabolism including 
glycolysis, the polyol-pathway, the tricarboxylic acid (TCA) cycle, and the urea cycle (Patassini et al. 
2019). Cellular process dysfunction, and possibly loss of wild-type HTT function (Mehler et al. 2019), 
lead to early changes in corticostriatal connectivity and eventually widespread degeneration.   
The predilection of mHTT to cause its most significant deleterious effects within the striatum and 
cortex is not consistent with the ubiquitous expression of HTT (Marques and Humbert 2013). The 
reason for the susceptibility of neurons within the striatum and cortex to mHTT is unknown (Morigaki 
and Goto 2017). Molecular complexity, metabolic rate, loss of wild-type HTT function and blood-
brain barrier permeability are all possible factors (Li et al. 1993, Strong et al. 1993, Francelle et al. 
2014, Mehler et al. 2019). The regions of the brain susceptible to mHTT are also susceptible to the 
neurotoxic effects of QA, which has been implicated in HD pathophysiology (see Section 1.4.4; 
Schwarcz et al. 2010, Rub et al. 2016). Furthermore, contradictory evidence has shown mHTT to both 
be toxic and protective to cell function (Davies et al. 1997, Saudou et al. 1998, Miller et al. 2010). The 
significance of the loss of wild-type HTT function versus a disruptive or toxic gain of function of the 
mHTT protein to the development of HD is still being debated (O'Kusky et al. 1999, Dragatsis et al. 




1.3.2 Cellular changes within the striatum in Huntington’s disease 
A heterogeneous pattern of neuron loss develops in the striatum during HD. The D2, enkephalin-
expressing MSNs of the striatum associated with the indirect pathway appear to degenerate first in 
the disease, such that the characteristic chorea is possibly a symptom of indirect pathway 
dysfunction since this pathway normally has an inhibitory effect on movement (Reiner et al. 1988, 
Deng et al. 2004). Both enkephalin and substance P containing GABAergic MSNs (Marshall et al. 
1983) and interneurons containing paravalbumin and choline acetyltransferase are eventually lost 
from the striatum as HD progresses (Cicchetti and Parent 1996, Reiner et al. 2013), while the 
interneurons containing somatostatin, neuropeptide Y, NADPH diaphorase, nitric oxide synthase and 
the medium sized GABAergic calretinin interneurons are relatively spared (Cicchetti et al. 2000, 
Waldvogel et al. 2015). The large, calretinin-expressing cholinergic interneurons are preserved until 
later stages of HD (Ferrante et al. 1987, Kowall et al. 1987). Table 1.1 summarises the major neuron 
populations within the striatum and their vulnerability during HD. Gliosis occurs within the striatum, 
especially the caudate nucleus, from early in HD, with an increase in oligodendrocytes, astrocytes 
and microglial (Waldvogel et al. 2015). The cellular changes, along with the gross pathological change 
of striatal atrophy and concomitant lateral ventricle dilation described earlier in Section 1.3, can be 











Table 1.1 Major neuron populations in the striatum and their vulnerability to Huntington’s disease 






Medium sized  GABA Matrix - GPe Dopamine 2 Lost 
spiny neuron  (Indirect pathway) Enkephalin Earliest 
(MSN, projection)   Calbindin (Matrix)  
          
Medium sized  GABA Matrix - GPi Dopamine 1 Lost 
spiny neuron  Matrix - SNr Substance P Early 
(MSN, projection)  Striosome - SNc Calbindin (Matrix)  
  (Direct pathway)   
          
Medium sized  GABA Matrix - Local Paravalbumin Lost  
aspiny neuron    Later 
(interneuron)     
          
Medium sized  GABA Matrix - Local Calretinin Spared 
aspiny neuron     
(interneuron)     
          
Medium sized  GABA All - Local Neuropeptide Y Spared 
aspiny neuron   Somatostatin  
(interneuron)   NADPH diaphorase  
   Nitric oxide synthase   
   Tyrosine Hydroxylase  
          
Large sized  ACh Matrix - Local Calretinin Lost 
aspiny cholinergic   Substance P Late 
neuron     
(interneuron)         
GABA: gamma-aminobutyric acid, Ach: acetylcholine, GPe: external globus pallidus GPi: internal 
globus pallidus, SNr: substantia nigra pars reticularis, SNc: substantia nigra pars compacta. 









1.4 Animal models of Huntington’s disease 
This section provides context for why the development of acute, excitotoxic sheep model of HD is 
important. First, the disadvantages of rodent models and the advantages of large animal models of 
neurodegenerative disease are discussed. An appreciation of the benefits of a sheep model of HD, 
compared to NHP models, is also provided. It is important to understand that large animal models 
can complement rodent models by addressing the disadvantage of rodent models, however large 
animal models are not envisioned as a replacement for rodent based research. An overview of the 
limitations of genetic models of HD is also provided in this section to provide context for the 
relevance of excitotoxic models. Finally, excitotoxic models of HD are discussed, with a focus on the 
use of QA.  
1.4.1 The disadvantages of rodent models of neurodegenerative disease 
The convenience, low cost and ethical advantages of using a lower order species mean that small 
animals, particularly rodents, are the first choice model for preclinical studies. Compared to humans, 
however, there are inherent properties of rodents which need to be carefully considered when 
drawing conclusions from any rodent HD study, including; the short life span, small brain volume, 
neuroanatomically dissimilar brain, differences in drug metabolism and the blood-brain barrier, 
genomic differences and disparate behavioural responses (Morton and Howland 2013, Howland and 
Munoz-Sanjuan 2014).  
The short life span of a mouse does not preclude it from reflecting the progression of a human 
disease that typically manifests in middle age and has a prolonged duration from diagnosis (average 
15 to 20 years; Roos 2010) as life span is relative (Dutta and Sengupta 2016). However, relative age at 
different developmental stages may influence the progression of a disease, as may the physiological 
causes of aging such as metabolic rate (Demetrius 2006). Furthermore, comparatively rapid 
development of a disease in a murine model that is typically of a chronic duration in humans may 




fully portray the disease seen in humans (Demetrius 2005, Demetrius 2006, Dutta and Sengupta 
2016).  
Significant neuroanatomical differences in rodents, compared to primates, include a different 
gross organization of the basal ganglia, the lisencephalic cortex in rodents versus the gyrencephalic 
cortex in primates (Rohlfing et al. 2010, Swanson 2018) and differences in neurogenesis (Lazarov and 
Marr 2013). However, cell and pathway organization of the human and rodent basal ganglia is 
similar, which indicates that while gross anatomy varies, functional anatomy is conserved (Brooks 
and Dunnett 2015). A small brain volume creates disparities in the application of therapeutic 
modalities when converted to clinical trials and may limit the application of techniques which identify 
and measure outcomes such as imaging and electroencephalography (EEG; Pouladi et al. 2013).  
One advantage of laboratory mice, genetic uniformity, may be a disadvantage when studying 
chronic progressive later-onset diseases with complicated multifactorial aetiologies (Duty and Jenner 
2011, Hugenholtz and de Vos 2018). Genetic and environmental variability in the human population 
may better enable sub-population manifestations of these diseases which may not be easily 
reproducible or even be apparent in a murine model with a very specific genotype (Lin 2008, Libby 
2015). Furthermore the genetic modification of laboratory mice almost certainly selects for alleles 
whose presence or effect on a study may not be fully appreciated (Mahajan et al. 2016), while 
genetic drift may affect reproducibility of a study (Taft et al. 2006).  
There is substantial conservation of genes between humans and mice (Monaco et al. 2015). 
However, homologous genetic and organizational similarity between humans and mice does not 
mean transcriptional or molecular similarity. For instance, the mouse transcriptional inflammatory 
and immune responses are very different to that of the human. This may be of particular relevance 
for complex diseases invoking multi-system responses like neurodegenerative disease (Mestas and 
Hughes 2004, Seok et al. 2013). Furthermore, dysfunction in homologous genes can manifest 




humans, mice, zebrafish and yeast found substantial pathological and phenotypic differences across 
species (Lollgen and Weiher 2015). 
1.4.2 Large animal models of neurodegenerative disease  
The basis for developing a large animal model of HD is that large animals may anatomically and 
physiologically align better with humans than do rodents (Morton and Howland 2013, McBride and 
Morton 2018). For example, because of the difference in size of the substantia nigra pars reticula and 
internal segment of the globus pallidus in rodents, most direct pathway medium spiny neurons in 
rodents project to the substantia nigra pars reticula, with a small percentage projecting to the 
internal segment of the globus pallidus. In primates, including humans, because the two regions are 
similar in size, an approximately even number of direct pathway medium spiny neurons target both 
regions (Reiner and Deng 2018). The substantia nigra in sheep has been demonstrated to be very 
similar to the human substantia nigra, as discussed in Section 1.2.1.  
Other advantages include larger brains and a more similar body size (which may assist ‘scaling-
up’), a longer life span (which may increase the accuracy of chronic disease models) and greater 
genetic variability between any two animals (that more closely approximates the human population 
and helps eliminate unrecognized and disadvantageous genomic effects seen in in-bred rodents; Dai 
et al. 2018, Herrmann et al. 2019, Murray et al. 2019). With the low correlation between preclinical 
and clinical trial success, development of a well-characterised large animal model of HD would 
provide another option for assessing efficacy and safety of a potential treatment that has shown 
promise in rodent models, prior to costly clinical trials.  
NHPs are the obvious large animal model to replicate human disease, with their similar anatomy, 
physiology and genome. Various excitotoxic and transgenic NHP models have been developed that 
have provided insights into HD (Ferrante et al. 1993, Brouillet et al. 1995, Burns et al. 1995, Palfi et al. 
1996, Kendall et al. 2000, Yang et al. 2008, Lavisse et al. 2019). The largest impediments to the 




difficulties and cost of adequate management of a NHP with dementia over an extended time period 
and the reluctance of the public to support NHP models of human disease (Morton and Howland 
2013).  
Farm animals circumvent some of the practical difficulties associated with the use of NHPs in HD 
research. In particular, pigs and sheep are easy to source, relatively economical to buy and house, 
ethically more acceptable to the general public, of a suitable size to be useful and manageable, and 
have very similar brains to humans, both in terms of size and anatomy (Dai et al. 2018, Morton 2018, 
Herrmann et al. 2019). For these reasons, transgenic large animal models of HD have been developed 
in pigs and sheep (Jacobsen et al. 2010, Yang et al. 2010, Baxa et al. 2013). 
1.4.3 Genetic models of Huntington’s disease 
There have been numerous fragment, full length and knock-in transgenic mouse models of HD 
developed (Mangiarini et al. 1996, Menalled et al. 2003, Slow et al. 2003, Gray et al. 2008, Southwell 
et al. 2017). Each of the transgenic mouse HD models have well documented advantages and 
disadvantages, with some excellent reviews detailing these models (Pouladi et al. 2013, Menalled 
and Brunner 2014, Brooks and Dunnett 2015). The main criticism of the transgenic HD mouse models 
has been a lack of overt neurodegeneration and full replication of the human pathology, and in 
particular the very long CAG repeats that are needed to induce pathology (Li and Li 2012).  
Large animal models of HD that express the full mHTT protein have been developed in sheep 
(Jacobsen et al. 2010), pigs (Yan et al. 2018), miniature pigs (Baxa et al. 2013) and NHPs (Yang et al. 
2008). The sheep model, OVT73, express a full length mHTT encoding cDNA with 73 polyglutamine 
repeats (CAG) under the control of the human HTT promoter. OVT73 express mHTT in all tissues, not 
just the brain, and have been shown to develop N-terminal mHTT fragment aggregates in the brain 
(Reid et al. 2013). Furthermore, immunohistochemistry of brains from OVT73 sheep revealed 
decreased expression of the spiny neuron marker DARPP-32 (Jacobsen et al. 2010). Circadian 




abnormalities have been reported in the full length mHTT miniature pig model (Askeland et al. 2018), 
however OVT73 has not developed any clinical signs of HD. OVT73 sheep express their wildtype HTT 
as well as the transgenic human mHTT (Jacobsen et al. 2010). The pig model has shown selective 
neurodegeneration of medium spiny neurons as well as rapid development of behavioural and motor 
abnormalities and early death (Yan et al. 2018).  
The miniature pig and sheep models have the advantage of longevity and reproducibility, with the 
oldest progeny of the transgenic sheep and miniature pig models currently being nine years old and 
five years old respectively. None of these models have fully captured the spectrum of 
neuropathological changes and symptoms seen in HD, which is an important reason why excitotoxic 
models continue to be relevant, however the miniature pig model is exhibiting gradually progressing 
neurodegeneration (Ardan et al. 2019) while the transgenic sheep model has increased plasma 
melatonin which is postulated to be neuroprotective (Morton et al. 2019). 
A miniature pig model that expressed an N-terminal mHTT fragment either died antenatally or 
had poor postnatal survival (Yang et al. 2010). The histological change in the miniature pig model 
replicated HD, including mHTT aggregates and cell apoptosis. However, the expression of the N-
terminal mHTT fragment only, which forms the insoluble aggregates seen in HD-afflicted neurons and 
is associated with cell malfunction and death, may have replicated an advanced stage of the disease 
neuropathologically, limiting the lifespan of the model (Li and Li 2015). The N-terminal mHTT 
fragment miniature pig model did not develop the full spectrum of symptoms seen in HD by life end, 
with their shortened life span limiting their usefulness (Morton and Howland 2013, Rogers 2016).  
The transgenic NHP model (Yang et al. 2008) produced histologic changes consistent with HD but 
few of the animals survived more than a few months. Disease in the NHP transgenic model 
progressed rapidly, not accurately replicating the disease (Chan et al. 2015). If the neuropathogenesis 




transgenic animal, including OVT73, expressing both wildtype HTT and mHTT may not fully replicate 
the disease or may take longer than predicted to replicate the disease. 
1.4.4 Toxic models of Huntington’s disease 
While the use of toxins to selectively lesion the striatum pre-date transgenic models of HD, toxic 
models continue to be highly relevant and frequently utilized in preclinical research (Cui et al. 2018, 
Emerich et al. 2019, Zhang et al. 2019). They can develop characteristic pathology not seen in 
transgenic models in an acute timeframe (Lelos and Dunnett 2018). However, they only replicate a 
portion of the neuropathology associated with HD, don’t develop characteristic aggregates and 
because they are acute, do not replicate the slow development and chronic nature of HD (Pouladi et 
al. 2013).  The main toxins that have been used to model HD are the glutamate analogues kainic and 
ibotenic acid, the N-methyl-D-aspartate (NMDA) receptor agonist QA and mitochondrial toxins 3-
nitropropionic acid (3-NP) and malonic acid. Table 1.2 summarises the major advantage and 
disadvantage for each toxin listed above.  
Kainic and ibotenic acid are excitotoxins that cause striatal degeneration and reproduce some of 
the histological changes seen in HD striatal degeneration (Coyle et al. 1983, Hantraye et al. 1990). 
Intrastriatal kainic acid produces epileptic activity rarely seen in HD patients and results in 
neurodegeneration in limbic structures outside of the striatum (Schwarcz et al. 2010, Nam et al. 
2017). Ibotenic acid produces circumscribed striatal lesions (compared with kainic acid) following 
intrastriatal injections and does not result in epileptic activity (Schwarcz et al. 1979, Schwarcz et al. 
2010). Neither compound is endogenous (Jorgensen and Olesen 2018, White et al. 2019) and 
therefore have not been implicated as a part of pathogenesis of HD.  
3-NP is an irreversible neurotoxin that inhibits mitochondrial energy production (Albin 2000) and 
produces spontaneous dose-dependent selective striatal pathology and clinical signs homologous to 
HD when administered systemically (Beal et al. 1993b, Brouillet et al. 1995). 3-NP replicates one 




al. 1997, Carmo et al. 2018). The reason for the susceptibility of the striatum to 3-NP is not fully 
known, however MSNs have been shown to be particularly sensitive to mitochondrial dysfunction 
(Pickrell et al. 2011, Crook and Housman 2013). 3-NP directly inhibits succinate dehydrogenase in the 
electron transport chain, generating reactive oxygen species that produce mitochondrial DNA 
damage and alter mitochondrial permeability further affecting the mitochondrial function (Tunez et 
al. 2010). 3-NP striatal lesions are homogenous to QA in representing HD striatal pathologic change 
(Kumar et al. 2010, Tunez et al. 2010). Because 3-NP is a mitochondrial inhibitor given systemically, it 
effects a wide range of tissues and has the potential to have a more deleterious effect on the health 
and welfare of an animal than QA which primarily causes a localized lesion (Alarcon-Herrera et al. 
2017).  
A reversible succinate dehydrogenase inhibitor, malonic acid, produces lesions similar to 3-NP 
when injected into the striatum (Beal et al. 1993a, Bazzett et al. 1995). Malonic acid lesions are less 
pronounced and more transient in nature compared to 3-NP and malonic acid models have been 
used to trial potential neuroprotective HD therapeutics (Fancellu et al. 2003, Sagredo et al. 2009, 
Kumar et al. 2013).  
Exogenous lesioning of the rodent and NHPs striatum using QA produces lesions that closely 
resemble HD pathological changes, with a reduction in GABA-producing spiny neurons and selective 
sparing of axons of passage, aspiny neurons containing somatostatin and neuropeptide Y and large 
cholinergic neurons plus a hypertrophy of glial cells, especially astrocytes. Grossly, atrophy of the 
striatum, with concomitant enlargement of the lateral ventricles occurs (Vonsattel et al. 1985, Beal et 
al. 1986, Bjorklund et al. 1986, Davies and Roberts 1988, Ferrante et al. 1993, Brickell et al. 1999, 
Lavisse et al. 2019). The gross and cellular pathological changes caused by QA resemble those of HD, 






Table 1.2 Common toxins used to create animal models of Huntington’s disease  
Toxin Action and delivery 
method 
Advantage Disadvantage 





Large area of necrosis 
with cystic cavity 
formation at centre of 




        
Ibotenic acid  Glutamate analogue.    
Acute striatal 
injection. 
HD like neuronal 
degeneration in well-
circumscribed 
injection region with 
sparing of transient 
and terminating fibres. 
Large area of necrosis 
with cystic cavity 
formation at centre of 
lesion. 




agonist.       
Acute striatal 
injection. 
HD like neuronal 
changes in transition 
zone may better 
model HD than Kainic 
or Ibotenic acid. 
Endogenous 
compound implicated 
in HD pathogenesis. 
Large area of necrosis 
with cystic cavity 
formation at centre of 
lesion. 









injections affect all of 






Animals often become 
very sick or die. Can 




        
Malonic acid Reversible succinate 
dehydrogenase 
inhibitor.   
Acute striatal 
injection. 
Similar lesions to 3-NP 
though also spares 
somatostatin neurons. 
Can be blocked. 
Milder, more transient 






QA is an intermediate of the kynurenine pathway which is important for L-tryptophan metabolism 
and nicotinamide adenine dinucleotide (NAD+) synthesis. QA is active in both neuronal and non-
neuronal tissues (Hogan-Cann and Anderson 2016). Physiological concentrations of QA in the 
different parts of the rat brain vary from 0.6 nmol/g in the striatum to 1.8 nmol/g in the cortex 
(Moroni et al. 1984). Endo- and exogenous elevation of QA is neurotoxic, with chronic exposure of 
rat striatal tissue to as little as 100 nmol QA capable of inducing excitotoxic damage (Whetsell and 
Schwarcz 1989).  
QA causes toxicity through multiple mechanisms; overactivation of primarily NR2A and NR2B 
subunit NMDA receptors resulting in massive calcium entry into the affected cells (de Carvalho et al. 
1996); increased glutamate release by neurons and inhibition of uptake by astrocytes increasing 
extracellular glutamate concentration and leading to overstimulation of the glutamatergic system 
(Tavares et al. 2002); oxidative damage including lipid peroxidation (Rios and Santamaria 1991); 
hyperphosphorylation of the light neurofilament subunit and glial fibrillary acidic protein resulting in 
destabilization of the neuronal and astrocytic cytoskeleton (Pierozan et al. 2010); mitochondrial 
dysfunction and energy depletion (Bordelon et al. 1997); and induction of autophagy and apoptosis 
(Guillemin et al. 2005, Braidy et al. 2014).  
One reason why QA models of HD are relevant is because early in the development of HD, QA is 
significantly elevated in the striatum and cortex (Guidetti and Schwarcz 2003). It is postulated that 
QA and other metabolites of the kynurenine pathway are involved in the pathogenesis of HD. Both 
microglia and macrophages produce QA under pathological conditions, potentiating 
neurodegenerative disease like HD (Schwarcz et al. 2010). Furthermore, not only does mHTT induce 
transcription of the kynurenine pathway, but also multiple unrelated genetic suppressors of mHTT 
toxicity converge on the kynurenine pathway suggesting that kynurenine pathway dysfunction may 
be an important link between mHTT production and neuron dysfunction and death (Giorgini et al. 




QA, whilst the cerebellum, substantia nigra, amygdala, medial septum and hypothalamus are more 
resistant (Schwarcz and Kohler 1983, Nakanishi 1992). The brain regions that are vulnerable to QA 
are not dissimilar to the brain regions most affected in HD (Rub et al. 2016). The possibility that QA is 
involved in the pathophysiology of HD influenced the decision to use QA to lesion the sheep striatum 
in this study. 
1.5 Phenotype testing in sheep models of disease 
Creation of an excitotoxic sheep model of HD requires the ability to phenotype the model. Sheep are 
ungulated, quadrupedal prey animals who naturally flock and spend approximately 16 hours a day 
grazing or ruminating. Because of their tendency to follow each other and act unpredictably when 
isolated, the common impression of sheep is one of stupidity. However, a range of sheep 
phenotyping studies disprove the orthodoxy on sheep intelligence (for examples, see below), 
allowing characterization of behavioural responses, cognitive function and motor performance and 
revealing phenotypic subtleties that were not previously appreciated.  
1.5.1 Cognition  
Sheep have been repeatedly shown to have a good memory and can discriminate between similar 
objects. Operant testing has shown that sheep are capable of discriminating between similar shapes, 
hue and brightness (Baldwin 1981, Bazely and Ensor 1989, Morris et al. 2010, Morton and Avanzo 
2011, Sugnaseelan et al. 2013, Knolle et al. 2017a) and can inhibit an already-started response (a 
response that deteriorates in HD patients; Knolle et al. 2017b) . Sheep can also remember and 
perform complex tasks when retested twenty two weeks after initial training (Hunter et al. 2015) and 
are capable of remembering and discriminating between fifty individual sheep faces for two years 
(Kendrick et al. 2001).  
Sheep have a good spatial memory, with significant improvements in time to traverse and 




deterioration in complex maze traversing performance when challenged with a muscarinic receptor 
agonist, scopolamine hydrobromide, which impairs memory function (Lee et al. 2006).The ability to 
remember and discriminate reinforces evidence that they have learning and memory neural systems 
in their frontal and temporal lobes analogous to those in humans, with a good capacity for learning 
and memory (Kendrick and Baldwin 1987, Kreiman et al. 2000, Kendrick et al. 2001, Ferreira et al. 
2004).  
Sheep have a high predicted level of cognitive capacity (McBride and Morton 2018). As well as 
discrimination and memory, sheep are capable of two complex executive decision making processes 
which are used for testing cognition in neurological disorders; namely reversal learning and 
attentional set-shifting (Morton and Avanzo 2011). Reversal learning is the ability to switch from a 
reinforced discriminatory choice to a previously incorrect choice (Izquierdo et al. 2017) while 
attentional set-shifting is the ability to transfer a reinforced belief to novel stimuli (Brown and Tait 
2016). Reversal learning and attentional set-shifting measure the functional capacity of the fronto-
striatal regions of the cerebrum and cognitive flexibility in a broader sense (Heisler et al. 2015). 
Comparatively, sheep are very capable of reversal learning and ranked third in a reversal index that 
included humans, other primates, pigs, dogs and rodents (McBride and Morton 2018). Executive 
decision making in the diseased sheep brain has not been previously published. Therefore, the two-
choice discrimination task performance of the QA-lesioned sheep, described in Chapter 4, is both 
novel and potentially very informative, given the reversal learning capability of sheep and the 
importance of the striatum for the task (Heisler et al. 2015, McBride and Morton 2018). 
High-throughput, semi-automated testing cognition in sheep is possible (McBride et al. 2015). 
However, the design of any operant system for sheep needs to minimise the effects of negative 
stimuli (Doyle et al. 2014). Minimising the effects of negative stimuli and ensuring high-throughput 
were key elements of the maze developed for the two-choice discrimination task described in 




1.5.2 Breed influence 
Breed-choice and breed standardization may be an important consideration in cognitive assessment 
study design in sheep. Welsh-Mountain sheep performed better than Norfolk Horned and Borderdale 
breeds in a study investigating navigational ability and self-image engagement (McBride et al. 2015) 
while Blue-Faced Leicester sheep performed significantly worse than Suffolk, Texel or Beulah breeds 
at reversal acquisition (McBride and Morton 2018). As well as breed considerations when selecting 
sheep for cognitive assessment studies, adverse in-utero and lamb conditions can affect cognitive 
capacity, including undernutrition and handling, as well as age and previous experience, highlighting 
the need for careful consideration of inclusion criteria for studies assessing cognitive functionality in 
sheep (Erhard et al. 2004, Coulon et al. 2015). Obtaining sheep from one property that were the 
same breed and from the same cohort, as described in Section 2.2, ensured that breed, age, gender, 
environment and management differences between properties, did not influence the results in the 
two-choice discrimination task. However, the performance of the Merino-Border Leicester cross 
sheep in cognitive assessment studies, in comparison to other breeds, is unknown. 
1.5.3 Circadian rhythms and activity monitoring 
Circadian rhythms and sleep homeostasis can be measured in sheep. Disruption of the sleep-wake 
cycle is a symptom of many neurodegenerative diseases (Homolak et al. 2018) (Askenasy 2001, Diago 
et al. 2018). Disturbances in sleep homeostasis and circadian abnormalities have been identified in 
the CLN5 Batten disease-affected sheep and the transgenic HD sheep through the use of EEG and 
activity monitoring (Morton et al. 2014, Perentos et al. 2016). An activity monitoring study was 
performed in the present study, as described in Appendix B. 
1.5.4 Motor phenotyping and rotation 
Motor changes are a well-defined part of the spectrum of clinical signs that occur in HD (Bates et al. 
2015), with the basal ganglia having an essential role in motor control (Dudman and Krakauer 2016). 




neurological examination, which is discussed in Section 1.5.5 and utilised in Chapter 3. Other 
techniques for motor analysis that have been utilised in sheep include kinematic performance 
analysis, using treadmill locomotion and motion capture technology, with analysis of fore- and hind 
limb gait analysis in healthy and experimentally injured sheep assessed (Faria et al. 2014, Safayi et al. 
2015, Safayi et al. 2016). The ability to identify motor changes in sheep is an important component of 
the development of a sheep HD model.  
Dopamine agonists, especially apomorphine, are frequently used in rodent and NHP studies to 
investigate if a striatal lesion is functional and unmask a motor phenotype in otherwise normal 
appearing animals (Giorgetto et al. 2015, Lavisse et al. 2019). Apomorphine is a non-selective 
dopamine receptor agonist with a rapid onset of action that stimulates locomotor activity (Beninger 
1983, Boyle and Ondo 2015). Rodent studies have shown that imbalance in dopamine signalling 
between the left and right striatum results in a side preference (Glick et al. 1977), measurable as a 
directional bias following administration of dopamine agonists in rodents and NHPs with striatal 
lesions (Molochnikov and Cohen 2014). Selective direct and indirect pathway activation within the 
unilateral striatum can also cause rotation, with direct pathway activation causing contralateral 
rotation and indirect pathway activation resulting in ipsilateral rotation (Kravitz et al. 2010). In NHPs, 
dystonia, dyskinesia and abnormal posture is often observed and measured in response to dopamine 
agonists, while rotation can be inconsistent (Brownell et al. 1994, Storey et al. 1994, Burns et al. 
1995, Kendall et al. 2000). Based on NHP studies (for examples, see references above), it was 
predicted that the QA-lesioned sheep would appear normal after initial surgical recovery. Therefore, 
dopamine agonist-induced rotation of the QA-lesioned sheep was investigated (described in Chapter 
4), as a technique for unmasking a phenotype in the functionally normal animals.  
1.5.5 The neurological examination of sheep 
There have been some comprehensive descriptions of the general neurological examination process 




examination has been described previously, however. Descriptions that generalize a neurological 
examination for use in a range of species that vary from a 30kg goat to a 500kg cow need to be 
refined for each species if a veterinary neurological examination is going to be a useful research 
technique. The general neurological examination of ruminants is similar to humans and other species 
in that it is a process that integrates signalment (age, gender, breed), history, distance examination, 
general physical examination, and a systematic evaluation of the peripheral and central nervous 
system to identify and localize neurological deficits and in some cases allow a specific disease entity 
to be diagnosed (Constable 2004). Typically, once clinical signs are localized, additional tests, either 
ante- or post mortem, are required to allow an accurate disease diagnosis with the post mortem 
examination of the nervous system an important part of the ruminant neurological exam (Nagy 2017, 
Wasle et al. 2017). 
The major clinical signs, pathology and basic mechanism of disease for sheep neurological 
conditions of veterinary importance are well described (see for an example an excellent review series 
of ruminant neurological disease in Australia by JW Finnie, PA Windsor and AE Kessell (2011)). 
Typically, the primary motivation of a neurological examination in sheep in a veterinary environment 
is to diagnose the presence or absence of a disease, not to grade the severity of that disease 
(Constable 2004). Characterisation of the clinical signs of neurological disease in sheep therefore 
emphasizes easily recognizable nerve deficit, motor, mentation and behavioural changes (Fecteau et 
al. 2017). Emotional, cognitive or social changes in sheep with neurological diseases are less 
recognized, as are the subtle pre-symptomatic and early clinical signs. 
There is no rating scale for any neurological diseases in sheep that quantify specific clinical signs 
and align those clinical signs with specific pathological changes to assess the severity and progression 
of a neurological condition in sheep. Recently a clinical examination protocol was developed to 




assist quick identification of possible scrapie affected animals in a suspect flock and was not intended 
to allow detailed grading of the disease in a single animal. 
1.5.6 Additional diagnostic techniques 
A wide range of techniques are utilized to diagnose and evaluate neurological conditions in 
ruminants (Nagy 2017). Apart from a clinical examination, standard veterinary diagnostic techniques 
for neurological conditions in ruminants include haematological and biochemical analysis, gross- and 
histo- pathology, microbiology, radiography (Lin et al. 2015) and ultrasonography (Guilbaud et al. 
2014).  
Additional diagnostic techniques to those described above, are typically performed in a research 
context. There are numerous examples of naturally occurring and experimentally induced sheep 
models of human neurological disease (see Table 1.3 for examples). Additional diagnostic techniques 
include; cerebrospinal fluid sampling (CSF; Scott 1995: See Appendix C), myelography (Mageed et al. 
2014), computerized tomography (CT; Birch et al. 2015), magnetic resonance imaging (MRI; Ertelt et 
al. 2016, Ella et al. 2017), electromyography (Bergmeister et al. 2016), electroretinography (Regnier 
et al. 2011), brainstem auditory-evoked potentials (Pierson et al. 1995, Griffiths et al. 1996), deep 
brain stimulation (Lentz et al. 2015) and EEG (Perentos et al. 2015, Oxley et al. 2016).  
Many of these additional diagnostic techniques, for example magnetic resonance (MR) modalities 
like MRI, magnetic resonance spectroscopy (MRS) and diffusion tensor imaging (DTI) have a paucity 
of published information specific to sheep. MRS and DTI investigation of the lesioned sheep brain, 








Table 1.3 Sheep models of human neurological disease 
Naturally occurring sheep diseases Mechanism of disease 
Neuronal ceroid lipofuscinosis 
(Batten disease) 
Lysosomal storage disease. CLN51, CLN62 or cathepsin D 
mutation.3  
Gaucher disease Lysosomal storage disease. Mutation in the β-
glucocerebrosidase gene.4 
Tay-Sachs disease Lysosomal storage disease. Deficiency of lysosomal 
enzyme β-N-acetylhexosaminidase A (Hex A).5 
Hereditary lissencephally 31-bp deletion in the RELN gene results in cerebellar 
hypoplasia and disorganisation of the cerebral cortex and 
hippocampus.6 
Scrapie A transmissible spongiform encephalopathy caused by 
infective distorted prion proteins.7 
Alexander disease Astrocytic disorder.8 
Hereditary cerebellar abiotrophy Loss of purkinje cells in the cerebellum and glial cell 
accumulation.9 
Experimentally induced diseases Mechanism of disease 
Stroke Proximal middle cerebral artery occlusion.10 
Foetal alcohol syndrome Maternal intravenous alcohol infusion during pregnancy.11 
Non-accidental infant head injury 
(shaken baby syndrome) 
Manual shaking of anaesthetised lambs.12 
Schizophrenia Lipopolysaccharide infection during pregnancy.13 
Foetal hypoxic brain damage Pregnant ewes housed in isobaric hypoxic chambers.14 
1(Jolly et al. 2002) 2(Jolly and West 1976) 3(Tyynela et al. 2001) 4(Karageorgos et al. 2011) 5(Torres et al. 2010) 
6(Perez et al. 2013) 7(Das and Zou 2016) 8(Kessell et al. 2012) 9(Harper et al. 1986) 10(Wells et al. 2012) 11(Birch 









1.6 Research significance, hypothesis and aims 
The value of large animal neurodegenerative disease models as an intermediary step in the 
therapeutic development process is well established (Morton and Howland 2013). The sheep offers 
numerous advantages as a large animal neurodegenerative disease model, including; large brain, 
anatomically and physiologically similar brain to humans, genetic diversity, relatively low cost, 
amendable to handling, easy to control and maintain and more acceptable to society as a medical 
research model than NHPs (Dai et al. 2018, Morton 2018). Sheep can reproduce human neurological 
disease, with multiple examples published (see Table 1.3).  
There is a need for excitotoxic large animal models of HD to be developed for use in validating pre-
clinical research undertaken in excitotoxic rodent models of HD. The first step in developing an 
excitotoxic large animal model of disease is to describe a technique for lesioning the striatum and 
assess if there is detectable pathology and phenotypic change. 
The hypotheses tested here were that: 
1) The sheep striatum can be lesioned with QA to create an excitotoxic sheep model of HD.  
2) Pathological change in sheep with QA lesions of the striatum will be detectable using MRI. 
3) Sheep with QA lesions of the striatum will have a detectable phenotype.  
Using techniques validated in rodents and NHPs, QA was injected into the striatum of sheep to create 
excitotoxic pathology. Sheep are ungulated quadrupedal ruminants with very different social and 
behavioural responses to rodents or primates. As such the motor, behavioural and cognitive 
symptomology that results from striatal lesioning likely manifests differently in sheep than NHPs or 
rodents. 
Therefore, the aims for the thesis were to: 
1) Describe a protocol for inducing QA lesions in the caudate nucleus of the striatum of sheep.  
2) Use a clinically relevant 3-Tesla MR scanner to identify lesion development and gross 




3) Render a standard veterinary neurological examination suitable for sheep and characterise 
the clinical manifestation of striatal lesions in the QA-lesioned sheep using the examination.  
4) Evaluate the usefulness of a neurological examination of sheep for diagnosing and 
characterising the phenotype of sheep with QA lesions of the striatum. 
5) Describe a technique for performing dopamine agonist mediated rotation studies in sheep. 
6) Investigate the ability of rotation studies to identify and characterise striatal pathology in 
QA-lesioned sheep.  
7) Establish a two-choice discrimination task to determine whether QA-lesioned sheep have 


















2.1 Ethics statement 
The experiment was conducted in accordance with the Australian Code of Practice for the Care and 
Use of Animals for Scientific Purposes (2013) and approved by the South Australian Health and 
Medical Research Institute (SAHMRI) (ethics approval: SAM161) and University of Adelaide Animal 
Ethics Committees (ethics approval: M-2015-106). 
2.2 Animals  
Sixteen castrated-male, 18 month old, Merino-Border Leicester cross sheep (Ovis aries, weight 58 – 
65 kg) were obtained from an approved source in South Australia and housed at SAHMRI, Gilles 
Plains, where all experimental procedures were conducted. Castrated-male sheep were used due to 
availability of these animals. The sheep were maintained as a flock in a single paddock prior to 
surgery and in groups of three animals in large outdoor group pens after surgery. Three days prior to 
surgery, the sheep were penned individually in an indoor facility where they remained until they had 
fully recovered from the surgery. An evaluation of demeanour, behaviour and ambulation of each 
sheep was performed at least twice daily for the entire experiment by experienced sheep handlers, 
with veterinary investigation performed if required. Sheep were fed meadow and lucerne hay once a 
day, with unlimited access to water and additional grain and Lauke Feedlot pellets (Lauke Mills, SA, 
Australia) when penned. Sheep were randomly assigned to either experimental or control groups.  
2.3 Experimental regime 
Six weeks prior to the first surgery, the sheep were habituated to facility staff and researchers. Sheep 
were randomly assigned to either an experimental or control animal group, with eight sheep in each 




sheep in each treatment group. Two surgical procedures were performed on each sheep, four weeks 
apart. QA (experimental group) or saline (control group) was infused into the left caudate nucleus 
(first surgery) and then the right caudate nucleus (second surgery). MRI scans were performed on the 
left and the right striatae of each sheep. These were conducted (1) prior to the first surgery, (2) one 
week after the first surgery, (3) five weeks after the first surgery and (4) sixteen weeks after the first 
surgery (Fig. 2.1A). Three neurological examinations were performed on the sheep; prior to the first 
surgery, two weeks after the first surgery and twelve weeks after the first surgery. Sheep underwent 
rotation studies pre-surgically and ten days, three weeks and sixteen weeks after the first surgery. 
Discrimination learning testing was performed twelve weeks after the first surgery (Fig. 2.1B). The 
sheep were euthanised at the end of the sixteenth week. After death, the brains were perfusion fixed 

















Figure 2.1 Diagram indicating the timeline of the study. Timeline of (A) surgical and MRI procedures 
and (B) phenotyping studies; neurological examinations (Neuro 1,2,3), rotation studies (R 1,2,3,4) 
and the two-choice discrimination task (Discrimination); ‘unilateral’ indicates the sheep only have a 
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2.4 Surgical procedure 
The surgery was based on a similar surgical procedure published in a study that injected an AAV9 
vector into the brain of transgenic HD sheep (Pfister et al. 2018). Experimental sheep had QA infused 
into the caudate nucleus during each surgery. Control sheep received saline infusions in lieu of QA. 
The surgeon (AO’C) was blinded to the treatment group of the sheep. Determination of the dose was 
based on the dose range used in rodent and primate studies (Popoli et al. 1994, Storey et al. 1994, 
Burns et al. 1995, Shear et al. 1998). A pilot study was performed to assess the effect of the chosen 
dose of QA in sheep (Appendix A).  
Immediately prior to surgery, QA (Sigma-Aldrich Co. LLC, St. Louis, MO, USA) was dissolved in 1 M 
sodium hydroxide (NaOH) and neutralised to pH 7 with 0.1 M phosphate buffered saline (PBS). A 
contrast agent, dimeglumine gadopentetate (Magnevist, Bayer, Germany), was combined with the 
QA to make a QA solution (QA 180 mM, gadolinium 2 mM), stored in a BD 1 mL tuberculin syringe. 
The syringe was placed on ice in a lightproof polystyrene container until required during the surgery. 
During the first surgery, QA (180 mM, 75 µl) or saline (75 µl) was infused into the head of the left 
caudate nucleus to create a unilateral (experimental) or sham lesion (control). During the second 
surgery QA or saline (at the same concentration and / or volume as previous) was infused into the 
head of the right caudate nucleus to create a bilateral striatal or sham lesion. Initial rostral, lateral 
and ventral stereotaxic coordinates for targeting the caudate nucleus were based on cadaver 
surgeries with the coordinates being progressively refined after each stereotaxic surgical procedure. 
The stereotaxic coordinate range for targeting the head of the caudate nucleus was taken with 
bregma as 0,0,0: rostral 19 – 24 mm, lateral 4 – 6 mm, ventral 22 – 24 mm. General anaesthesia was 
induced in the sheep using 5 mg/kg of 100 mg/mL ketamine hydrochloride (Ceva Animal Health Pty 
Ltd, Australia) and 0.4 mg/kg of 5 mg/mL diazepam (Pamlin, Ceva Animal Health Pty Ltd, Australia) 
administered via the jugular vein. Endotracheal intubation allowed sheep to be mechanically 




inserted into the jugular vein and lactated Ringers solution (Hartmann’s, Baxter Healthcare Pty Ltd, 
Australia) was administered at a rate of 10 mL/kg/hour. Sheep received 2 mg/kg of 50mg/mL 
carprofen (Carprieve, Norbrook Laboratories Australia Pty Ltd) before being positioned in a 
stereotaxic frame (Kopf, model number 1630; Tujunga, CA, USA). Sheep were given 3 g of 1 g 
cefazolin sodium (Cefazolin-AFT, AFT Pharmaceuticals, New Zealand) intravenously during surgery. 
Post-surgery, 22 mg/kg of 300 mg/mL procaine penicillin (Depocillin, MSD Animal Health, Australia) 
was administered daily for three days. 
Sheep were placed in the sphinx position on a large elevated cylindrical pad; the ventrum of the 
sheep rested on top of the pad and the limbs extended down each side of the cylindrical pad, 
minimising risk of pressure neuropathy or myopathy. The head was placed in a large animal 
stereotaxic frame. Ear bars and orbital notch prongs were adjusted such that a line between the 
ventral orbital rim and the horizontal canal of the external auditory meatus was parallel to the 
horizontal plane and perpendicular to the manipulator apparatus. The cranium was shaved and 
aseptically prepared. Sterile surgical techniques were maintained throughout the surgical procedure. 
A monopolar electrocautery was used to create a 3 cm curvilinear incision through the dermal and 
subcutaneous layers just caudal to the poll of the sheep's head. A rostral 3 cm incision was extended 
perpendicular to the curvilinear incision. The dermal, subcutaneous and periosteal layers were 
reflected to expose the skull. Bregma was identified and marked as a reference point using a surgical 
pen. A 3 – 4 mm burr hole craniotomy was performed to expose the dura using a Dremel 8220 drill 
(Dremel, Racine, WI, USA) at appropriate coordinates rostral to bregma and lateral to the midline. 
The manipulator was mounted on the Kopf stereotaxic frame at the predefined rostral and lateral 
coordinates and a convection-enhanced delivery (CED) cannula (MRI Interventions, Irvine, CA, USA) 
secured to the manipulator. The CED cannula was attached to a 25 cm luer lock extension set that 
was secured to the syringe that contained the QA or saline. An infusion pump (New Era Pump 




and extension line. A 1.5 mm incision was made through the dura permitting the CED cannula to 
traverse the dura, while ensuring the dura closely adhered to the cannula to minimise CSF leakage.  
A micro-manipulator was used to lower the CED cannula to the predefined ventral coordinate 
from the dural surface and the exposed skull covered with saline-soaked gauze. QA or saline infusion 
was started five minutes after the CED cannula was lowered to the ventral coordinate to allow tissue 
disrupted by the CED cannula to stabilise. QA or saline was infused at a rate of 2 µl/minute until the 
desired volume was completed. The CED cannula was left in situ for ten minutes after the infusion 
ended before being slowly withdrawn over ten minutes. Bone wax (Ethicon, NJ, USA) was used to 
seal the craniotomy after CED cannula removal. The wound was irrigated with saline and closed using 
monofilament absorbable suture (PDS, Ethicon, NJ, USA). The sheep was removed from the 
stereotaxic frame and recovered from the anaesthetic.  
2.5 Magnetic resonance methodology 
Sheep were anaesthetised during each MRI. Anaesthesia was induced with 20 mg/kg of 1000 mg/g 
thiopentone sodium (Ilium, Troy Laboratories, Australia), administered to effect in the jugular vein 
and maintained using 2% isoflurane. T1-weighted, magnetisation-prepared, rapid gradient-echo (T1-
MPRAGE) sequences were performed on a 48 channel 3-Tesla Siemens Skyra (Siemens AG, Erlangen, 
Germany) MR scanner with posterior 20 channel head coil and 18 channel surface body coil. DTI was 
performed using a bipolar scheme, resolution = 2.1 mm3; repetition time (TR) / echo time (TE) = 3000 
/ 100 ms, field of view = 240 mm, base matrix = 112, simultaneous multi-slice factor 2, 256 diffusion 
directions, b = 0, 1000 s / mm2. Diffusion weighted imaging was performed with a readout 
segmentation of long variable echo-trains monopolar scheme, 4-scan trace, resolution = 1.3 × 1.3 × 
1.5 mm; TR / TE 1 / TE 2 = 7870 / 69 / 115 ms, field of view = 220 mm, base matrix = 164, generalised 
auto-calibrating partial parallel acquisition / 2, b = 50, 500, 1000 s / mm2. Single voxel spectroscopy 
was performed using a point resolved spectroscopy sequence, TR / TE = 2170 / 30 ms, 144 averages, 




the head of the caudate nucleus (Fig. 2.2). Voxel size was optimised to maximise signal-to-noise ratio 
whilst preventing inclusion of anatomical structures outside of the area of interest. Spectra were 
assessed for variance from the study mean before inclusion into the study, with spectra 1.0 or 
greater below the study mean excluded. An inline frequency correction was used to compensate for 
any drift in the spectra due to motion. A water-unsuppressed acquisition was also acquired to 
provide a concentration reference.  
Figure 2.2 Region of interest placement for single voxel spectroscopy. Representative example of 
region of interest placement (white box) in A) coronal, B) axial and C) sagittal orientation, 









2.5.1 Magnetic resonance spectroscopy data processing 
Automatic time-domain signal processing was performed using Tarquin (Wilson et al. 2011). Tarquin 
uses a constrained least-squares approach to estimate signal amplitudes for metabolites in the time-
domain. Tarquin has been previously used to process ovine MRS data from pre-term lambs with 
ventilator induced brain injuries (Skiold et al. 2014). The water peak of the unsuppressed spectrum 
was used as an internal reference to calculate concentrations of the following metabolites: glutamine 
(Gln), glutamate (Glu), myo-inositol (Ins), N-acetylaspartate (NAA), N-acetylaspartate and N-
acetylaspartylglutamate (TNAA), glycerophosphocholine and phosphocholine (total choline) and 
creatine and phosphocreatine (total creatine).  
2.5.2 Anatomical and diffusion tensor imaging data processing 
DTI data processing was performed using vendor software (Siemens AG, Erlangen, Germany), 
measured as fractional anisotropy (FA). Tensors were reconstructed and inspected visually. FA maps 
were produced inline on the scanner, and were analysed using ITK-Snap software (Yushkevich et al. 
2006). Using the trace weighted images, spherical 67.5 mm³ regions of interest were drawn over the 
middle of the lesion in the head of the caudate nucleus, if visible, or the middle of the head of the 
caudate nucleus if no lesion was visible. These regions were then translated to the FA maps for 
quantification. ITK-Snap software was also used to visualise and segment lesions visible on the T1-
MPRAGE images and calculate lesion volumes. 
2.5.3 Magnetic resonance spectroscopy and diffusion tensor imaging statistics 
Statistical analysis of MRS and DTI data was performed using SPSS-25 (IBM, Armonk, New York, 
United States). Acute (one week after surgery), and chronic (five to sixteen weeks after surgery) 
changes in metabolite concentrations and FA were compared between QA-lesioned and saline-
treated striatae and with unlesioned striatae using a linear mixed-effects model with p < 0.05 




lowest Akaike’s information criterion. Model assumptions and normality were ascertained using a 
residual value histogram and scatter-dot plots.  
2.6 Neurological examination procedure 
Two experienced veterinarians (AO’C and one other) performed each examination. Both neurological 
examiners were blinded to whether a sheep was an experimental or control animal and did not see 
diagnostic MRI, however one veterinarian (AO’C) assumed primary responsibility for the sheep and 
therefore was not blind to the planned proportion of sheep that received QA lesions or the surgical 
recovery. The surgical recovery was not discussed by the two veterinarians. 
2.6.1 Neurological examination protocol 
Neurological examinations were based on a standard canine veterinary neurological examination (de 
Lahunta and Glass 2009), modified to be suitable for sheep. Neurological examinations were 
performed using a systematic, repeatable method for consistency between examinations and sheep. 
All sheep recovered fully from surgery and appeared functionally normal prior to post-surgical 
neurological examinations. The day before the neurological examination, the sheep were housed in 
individual pens in the testing area (Fig. 2.3) to give them time to acclimatize to the testing area. 
Sheep were examined individually.  
Initially a distance examination was performed with demeanour, behaviour, gait (without exerting 
pressure to move) and posture of each sheep assessed in their individual pen. Gait was further 
evaluated using a twenty five metre ‘L’ shaped race that led into a four metre by four metre square 
pen. The race contained a 30 cm high, 40 cm wide obstacle that traversed the race at the start of the 
long arm of the ‘L’ forcing the sheep to jump. Three cylindrical bins, 100 cm high by 60 cm wide were 
placed five metres past the jump in a pattern that forced the sheep to zig-zag. One examiner was 
placed at each end of the race to allow gait assessment from the front and back of each sheep as the 




while circling the sheep clockwise and anticlockwise. Examination of the gait was used to detect 
evidence of paresis, ataxia, and hypo- or hypermetria. 
 
Figure 2.3 Diagram of the neurological examination facility. The solid black rectangle represents a 
30cm high, 40cm wide step. The three solid black circles represent three 100cm high, 60cm wide 
bins. The * symbols indicate where observers stood as sheep navigated the L-shaped race, shaded 
grey, that began at the start gate (dashed line) and finished at the circling pen.  
 
After the distance examination was performed, each sheep was brought into a smaller three 
metre by three metre pen for the rest of the neurological examination. Pupil size and location, 
menace reflex, palpebral reflex, dazzle response, direct and indirect pupillary light reflex, nystagmus 
(presence of physiologic, absence of spontaneous), facial and pinnae sensation and response, facial 
symmetry, swallowing and tongue movement were evaluated to assess cranial nerves: II (optic), III 
(oculomotor), IV (trochlear), V (trigeminal), VI (abducens), VII (facial), VIII (vestibulocochlear), IX 
(glossopharyngeal), X (vagus) and XII (hypoglossal). Each cranial nerve assessment was described as 












Muscular tone and evidence of atrophy was evaluated by palpating the sheep while standing and 
exerting appropriate pressure over the front and hind limbs. Muscle tone was described as hyper, 
normal or decreased. Cutaneous trunci, tail and anal tone and the perineal reflex were also assessed 
while the sheep was standing and described as normal, decreased or absent. 
Postural reactions were assessed with both examiners handling the sheep. Postural reactions 
were described as either normal, decreased or absent. The sheep were lightly restrained and not 
allowed to lean on the examiner or any object. Knuckling of the distal limb, crossover of fore and 
hind limbs, bilateral side-hopping and wheelbarrowing of fore and hind limbs was assessed. For the 
side-hopping assessment, one examiner supported the hind limb and abdomen while the other 
examiner supported the front limb and elevated the head and neck to the level of the horizontal 
plane. For the wheelbarrowing, the elevated limbs were held at the horizontal plane with one 
examiner holding each limb.  
After assessment of postural reactions, the sheep was placed in lateral recumbency. Fore- and 
hindlimb flexor withdrawal and hindlimb patellar reflexes were evaluated as hyper, normal, 
decreased or absent. Presence or absence of a crossed extensor response was noted. The sheep was 
then allowed to stand with coordination of the standing process and time to stand evaluated as 
normal or decreased. At the end of all the individual neurological examinations, the sheep were 
group housed in a four metre by four metre pen and behaviour in a flock evaluated as either 
appropriate or inappropriate with any inappropriate behaviour described.  
2.7 Rotation studies 
Rotation studies were performed with sheep placed individually into animal pens. Pens (2.0 metres 
wide by 3.0 metres long by 1.5 metres high) were under cover, with compacted clay floors and a 
black corflute (Bunnings, Australia) lining on three sides, leaving an entrance on the fourth side 
unlined. During each rotation study, sheep were put into the rotation pen the day before recording, 




rotation recordings were performed in the morning (between 0900 and 1200). A Logitech C920 HD 
Pro Webcam (Logitech, Switzerland) mounted on a Libec TC-6 camera tripod (Heiwa Seiki Kogyo Co., 
Ltd, Japan) was placed in front of the rotation pen on the morning of the recording. The camera was 
positioned so that it captured all activity in the pen. Prior to the start of recording, sheep were given 
thirty minutes after camera set-up to become accustomed to the camera. Sheep movement was 
recorded for sixty minutes, and then each sheep was given a subcutaneous 0.1 mg/kg apomorphine 
hydrochloride (Sigma-Aldrich Co. LLC, St. Louis, MO, USA) injection, dorsally at the midline base of 
the neck. The injection area had previously been shaved to allow visualization of the injection site. 
The activity of the sheep was then recorded for a further sixty minutes. Sheep were undisturbed 
during each sixty minute recording period. During each rotation study, the investigator (AO’C) 
remained within hearing distance, but not visual contact, of the sheep.  
2.7.1 Rotation data analysis 
Rotation was quantified from video recordings. Only full 360° rotations were counted. For each 
rotation, the time that had elapsed since the commencement of the study and the direction of 
rotation was recorded. Net rotational activity was the difference between total rotation in a direction 
ipsilateral to the side of the first surgery and total rotation in a direction contralateral to the side of 
the first surgery. Since the investigator (AO'C) knew which side had been injected, he, while 
remaining blinded to experimental group, made a prediction of which sheep belonged to which 
experimental group, based on rotational data. Sheep were labelled as ‘likely to be QA-lesioned’, 
‘likely to be saline-treated’ or ‘unsure’ (if the data were equivocal for a sheep).  
2.7.2 Rotation statistics  
SPSS 25 (IBM, Armonk, New York, United States) was used to perform statistical modelling. Net 
rotation data was analysed using an unpaired t-test for comparisons between saline-treated and QA-
lesioned sheep and a paired t-test for self-control comparisons. For all statistical comparisons, p < 




2.8 Two-choice discrimination learning 
2.8.1 Test apparatus 
A novel apparatus was designed, based on a previously published apparatus (Morton and Avanzo 
2011). An 8.0 metre by 4.25 metre test apparatus was constructed inside a raised barn with wooden 
slat floors (Fig. 2.4). The test apparatus comprised of a central corflute-lined chute that opened into a 
corflute-lined, longitudinally divided decision pen. A single square plastic bucket (Award Storeaway 
27 L, Award Brands, Australia) was placed in a pre-marked central position at the end of each 
decision arm immediately in front of the decision arm exit gate. One of the two buckets was yellow 
and the other was blue. A race connected the decision pen back to the starting pen. Gates situated at 
the start point and entry and exit of each arm of the decision pen controlled sheep flow through the 
apparatus. Gates were operated using a cable-pulley system by the operator. This was situated to the 
left of the apparatus, so that the operator was able to manipulate all of the gates from one location. 
A Logitech C920 HD Pro Webcam was mounted above the decision pen with a HP Compaq LA2306x 
computer screen orientated out of view of the sheep to allow the operator to monitor sheep 
progress via the screen, without looking at the sheep. Individual holding pens were located to the left 




Figure 2.4 Plan of the discrimination testing apparatus. Arrows indicate direction of sheep 
movement. Individual sheep were moved from the holding pen into the start pen. Sheep were 
unable to enter the chute and see the buckets until the start gate was opened. When sheep made a 
decision, the backing gate was closed behind them. The sheep would exit past the bucket in the 
decision arm and return to the start position or holding pens as appropriate. The start pen gate could 
be closed behind the sheep at the starting position forming a pen when the start gate was closed. 





2.8.2 Habituation and training 
Sheep were habituated as a single large group to the test apparatus, including direction of flow and 
gate movements, daily during the week, for one month prior to their initial surgery. Two weeks prior 
to the start of testing, sheep were split into groups of two to three animals and housed in group 
pens. Each group of sheep underwent sixty to ninety minutes of training per day. The order that each 
group came in for training rotated each day. Individual sheep were progressively introduced to the 
various operating elements of the test apparatus and acclimatized to the test protocol. Black buckets 
were used during training. The end of training was when an individual animal was completing the 
test protocol in a calm manner. The operator always wore a white lab coat when habituating and 
training sheep and conducting sheep movements associated with the test apparatus. 
2.8.3 Test protocol 
The test protocol utilised a food reward to drive sheep behaviour. Simple two-choice discrimination 
learning was tested. During the acquisition phase of the two-choice discrimination learning task, the 
sheep learnt to discriminate between positively (S+) and negatively (S-) associated novel stimuli. 
During the reversal phase of the two-choice discrimination learning task, S+ and S- were switched, so 
the previous S+ becomes the S-. Half of the sheep were each assigned the yellow or blue bucket as S+ 
for the acquisition. The S+ bucket contained a five gram grain reward placed so that it could not be 
viewed until the head of the sheep was immediately over the bucket, while the S- bucket containing 
no grain. Small open packets of grain were taped behind each decision arm exit gate to reduce 
olfactory assistance arising from the grain reward. The operator opened the start gate allowing the 
sheep to exit the starting pen and enter the central chute. The central chute allowed the sheep to 
see both S+ and S- and to select the decision arm down which to progress. The sheep was deemed to 
have made a choice when it reached a point where the backing gate on each decision arm could be 
closed, restraining the sheep in the decision arm. The sheep were unable to visualise grain in the S+ 




trials of the first session for acquisition and reversal. If the sheep selected S+, they were able to eat 
the grain reward. The exit gate of the decision arm was opened after the animal had eaten the grain 
if they selected S+ or after a time out of twenty seconds if they selected S-. The decision arm in which 
S+ / S- was presented in each trial was randomised, with a random sequence prepared prior to the 
session using a Microsoft Excel (Microsoft Corporation, Redmond, WA, USA) random function. Sheep 
performed ten discrimination trials per session. After the tenth repeat, they were returned to their 
holding pen. Sheep were considered to have learned a discrimination when they achieved 8 / 10 
correct (80%) or greater in two consecutive sessions. Only the operator was present during testing.  
2.8.4 Discrimination data analysis and statistics 
SPSS 25 (IBM, Armonk, New York, United States) was used to perform statistical modelling. 
Acquisition and reversal performance were compared between experimental groups using the 
number of sessions required to reach a criterion of two consecutive sessions of 80% or greater 
correct. The data were also reanalysed, comparing the number of trials required to achieve six 
correct choices-in-a-row. Discrimination data was analysed using an unpaired t-test and the mean ± 
SD were reported. For all statistical comparisons, p < 0.05 was considered to be significant.  
2.9 Histology 
At the conclusion of the study, sheep were killed humanely with an intravenous injection of 0.5 
mL/kg of 325 mg/mL pentobarbitone sodium (Lethabarb, Virbac, Australia). After death the heads 
were perfusion-fixed with 10% neutral buffered formalin and the brains were removed and placed in 
10% neutral buffered formalin. A midline sagittal incision split the brain into two halves. A coronal 
slice was made through the optic chiasm, which extended up through the head of the caudate 
nucleus, transecting the QA-lesion site visible on MRI. Sequential coronal blocks (5 mm) were cut 
rostrally and caudally from the initial incision. Each block was paraffin embedded. Sections (5 µm) 
were cut from the face of each block using a microtome. Light microscopy was performed to examine 




2.9.1 Haematoxylin and eosin staining for paraffin sections  
Sections were mounted on charged glass microscope slides (Superfrost Plus microscope slides, Lomb 
Menzel-Glaser, USA) and heated at 60°C for twenty minutes. The sections were then dewaxed in two 
changes of xylene (two minutes each change), followed by three changes of absolute alcohol (two 
minutes each change) and then gently washed in running tap water for three minutes. After a brief 
rinse in distilled water, the sections were stained with freshly filtered Lillie-Mayers haematoxylin 
(POCD Healthcare, Australia) for three minutes, rinsed in running tap water for one minute, 
differentiated by quickly dipping ten times in 1% acid alcohol, washed in running tap water until 
clear, blued in saturated aqueous carbonate solution for one minute, washed in running tap water 
for thirty seconds, counterstained in filtered 1% alcoholic eosin for one minute, dehydrated in 3x 
three minute changes of absolute ethanol, cleared in 2x three minute changes of xylene, mounted in 
DePex mounting medium and cover slipped. 
2.9.2 Immunohistochemistry 
The primary antibodies used were; rabbit anti-glial fibrillary acidic protein (GFAP, #Z0334, Dako, 
Denmark) diluted 1/13,000 and rabbit anti-ionised calcium binding adaptor molecule 1 (Iba1, #016-
20001, Wako, USA) diluted 1/500 in 2% normal donkey serum (NDS). The secondary antibody used 
was biotinylated donkey anti-rabbit (#715-065-152, Jackson ImmunoResearch, USA) diluted 1/1000 
in PBS.  
Sections were mounted on charged glass microscope slides (Superfrost Plus microscope slides, 
Lomb Menzel-Glaser, USA) and heated at 60°C for twenty minutes. The sections were then dewaxed 
in two changes of xylene (two minutes each change), followed by three changes of absolute alcohol 
(two minutes each change), and then gently washed in running tap water (three minutes). After a 
brief rinse in distilled water, antigen retrieval was performed by microwave heating the sections to a 
gentle boil in 10 mM sodium citrate buffer, pH 6 for ten (GFAP) or twenty (Iba1) minutes. Slides were 




running tap water (three minutes). All subsequent steps were performed at room temperature in a 
humidified chamber. Sections were circled with a peroxidase-antiperoxidase pen (DAKO, Denmark), 
rinsed in two changes of PBS (five minutes each) and then incubated in 10% NDS (Jackson 
ImmunoResearch, USA) in PBS for sixty minutes. The NDS was drained from the slides and the 
sections were incubated with the primary antibody overnight. The following day, the sections were 
rinsed in three changes of PBS (five minutes each) prior to blocking endogenous peroxidase by 
incubating sections in 0.3% hydrogen peroxide in PBS for thirty minutes. Slides were rinsed in three 
changes of PBS (five minutes each), and then incubated in the secondary antibody for sixty minutes. 
Slides were rinsed in three changes of PBS (five minutes each), incubated in Vector Avidin-Biotin 
Complex (ABC) reagent (Vector Laboratories, USA) for sixty minutes and rinsed again in three 
changes of PBS (five minutes each). The antibody reaction was visualised using diaminobenzidine. 
Sections were then rinsed in running tap water for five minutes, dehydrated in three changes of 
absolute ethanol (three minutes each), cleared in two changes of xylene (three minutes each), 
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This chapter describes the surgery used to create an acute QA model of HD in sheep (Ovis aries). It 
also describes the use of a sheep specific veterinary neurological examination to investigate the 
clinical signs of ovine striatum pathology. The value of the veterinary neurological examination in the 
symptomology investigation is assessed. Sixteen sheep underwent two surgeries, four weeks apart, 
in which either QA or saline was infused into the left (unilateral) and then the right (bilateral) 
caudate nucleus. Neurological examinations were performed pre-surgically, two weeks after the 
unilateral surgery and eight weeks after the bilateral surgery. Examining veterinarians were blind to 
treatment group. Evidence of laterality and hind limb motor dysfunction was identified in the QA-
lesioned sheep. The neurological examination identified clinical signs in two out of eight saline 
control sheep and four out of eight QA-lesioned sheep after the unilateral surgery and three out of 
eight saline control sheep and seven out of eight QA-lesioned sheep after the bilateral lesion surgery. 
There was no association between clinical profile and lesion size or location. While the neurological 
examination was moderately useful for identification of QA-lesioned sheep, it was not informative 
about lesion characteristics.  
3.2 Background 
Sheep have basal ganglia and other brain structures anatomically similar to primates (including 
humans) and are increasingly being recognised as an important species for translational 
neurodegeneration research (Morton and Howland 2013). Functional anatomy of the basal ganglia 
and their outputs, however, is poorly characterised in sheep. As sheep are ungulate ruminant 
quadrupeds, their pyramidal and extrapyramidal pathways are likely to be different to those of 
rodents and primates, which utilise fine motor control to reach, grasp and climb. It thus seems 
unlikely that ruminants with striatal dysfunction will have a clinical presentation similar to that of 




A standard veterinary neurological assessment has never been developed for rodents and is not 
possible in NHP neurodegenerative models for reasons of safety. Rather, a battery of specific 
neurological tests are used to identify and characterise striatal dysfunction in these species, e.g. 
forelimb movement patterns, elevated body swing test and grip strength test in excitotoxin lesioned 
rats (Antunes et al. 2013, Klein et al. 2013, Gill et al. 2017), or staircase based and object retrieval-
detour tasks in NHPs (Kendall et al. 2000, Roitberg et al. 2002). A standard veterinary neurological 
examination has been developed for canines (de Lahunta and Glass 2009). The canine neurological 
examination was adapted for sheep in this study.  
The first aim of this study was to describe a technique to inject QA into the caudate nucleus of 
sheep. The second aim of this study was to identify gross pathological change in the QA-lesioned 
sheep using anatomical MRI. The third aim of this study was to characterise the clinical manifestation 
of striatal lesions in sheep using a standard veterinary neurological examination that was rendered 
suitable for sheep. The fourth aim of this study was to evaluate the usefulness of a neurological 
examination of sheep for diagnosing and characterising the phenotype of sheep with QA lesions of 
the striatum. By performing a standard veterinary neurological examination on sheep with QA-
induced striatal lesions, it is possible to determine the value of the examination as part of a toolkit 
for assessing neurological function in ruminant models of neurodegenerative disease. The data 
obtained enabled construction of a symptom profile for sheep with significant striatal damage. 
3.3 Results 
3.3.1 Surgical recovery 
After the left side (unilateral) surgery, one control and five QA-lesioned sheep developed hindlimb 
paresis and proprioceptive deficits. In four of the eight QA-lesioned sheep, clinical signs were mild, 
with a narrow, slightly crouched hindlimb posture and crossing over of the hind limbs when standing 
or turning. One QA-lesioned sheep (QA8) developed mild to moderate hindlimb paresis with 




resist pressure over the hindlimbs. Two QA-lesioned sheep with hindlimb dysfunction (QA7, QA8), 
showed handling-induced orofacial dyskinesia and temporary inappetence. One of the QA-lesioned 
sheep with mild hind limb dysfunction (QA4) developed intermittent spontaneous anticlockwise 
circling, which was exacerbated by handling. Two other QA-lesioned sheep had reduced left pinna 
tone (QA4, QA5). All observable clinical signs resolved completely within one week, with sheep 
appearing normal under observation thereafter. 
After the second surgery, one control (Control 8) and one QA-lesioned sheep (QA4) developed 
mild hindlimb paresis and mild proprioceptive deficits. Two QA-lesioned sheep developed handling-
induced orofacial dyskinesia and temporary inappetence (QA5, QA6), with one of the two sheep 
developing mild hindlimb paresis and the other sheep developing a narrow hindlimb stance with 
upright fetlocks, a wide-based forelimb stance, a very mild intention tremor and a tendency to circle 
left. All observable clinical signs resolved completely within one and a half weeks.  
3.3.2 Neurological examination 
Table 3.1 provides a summary of findings from the neurological examinations of the control and QA-
lesioned sheep. There were no abnormalities detected during the pre-surgical neurological 
examinations of the sheep. Clinical signs were identified in two out of eight unilateral saline-treated 
(control) sheep and three out of eight bilateral saline-treated sheep during the post-surgical 
neurological examinations. Two control sheep had possible or very mild hindlimb dysfunction 
identified during the unilateral examination, with one of those two sheep having a side preference 
during the bilateral examination. Two different control sheep had possible or very mild hindlimb 
dysfunction identified during the bilateral examination. Per examination, clinical signs identified in 
control sheep were mild and limited in number, compared to the identification of multiple clinical 
signs in QA-lesioned sheep. 
Three out of eight QA-lesioned sheep had evidence of hind limb dysfunction including reduced 




those three sheep spontaneously circling to the right. The sheep that developed mild to moderate 
hindlimb paresis and orofacial dyskinesia following unilateral surgery (QA8) was the most clinically 
affected sheep with evidence of hindlimb paresis during examination. Interestingly, the other sheep 
with post-surgical orofacial dyskinesia and hind limb dysfunction (QA7) had no clinical findings during 
the unilateral examination.  
Seven out of eight QA-lesioned sheep had evidence of hind limb dysfunction and laterality during 
the bilateral examination, including circling, gait abnormalities, postural deficits and decreased hind 
limb tone. The most clinically affected sheep during the bilateral neurological examination was also 
the most clinically affected sheep during the unilateral neurological examination (QA8). The two 
sheep with the most severe clinical signs during surgical recovery after the second surgery were the 
least affected during the bilateral neurological examination. During the bilateral neurological 
examination, the sheep with upright hindlimb fetlocks during surgical recovery (QA5) successfully 
jumped out of a holding pen when initially approached and only had a mildly abnormal narrow 
stance and a slow yet coordinated rise from lateral recumbency, while the other sheep with orofacial 






Table 1. Neurological examination results for individual sheep 



















Spontaneous slow moderately tight circling left 
Narrow hindlimb stance 
Hind foot placement frequently rotated when standing 
Occasional overextension left-hind when circling 
Side-hopping mild delay left hind 







Reluctant to circle to left 

















Occasional right hind limb scuff and knuckling- when 
circling 






Reluctant to circle to left 
Occasional overextension right-hind when circling 
Incorrect correction of cross over right hind 
Slow hindlimb wheelbarrow 
Collapsed once on forelimb wheelbarrow 
Slow coordinated rise from lateral recumbency 
Mild right hind muscle atrophy 















Spontaneous moderately-fast tight circling right 
Reluctant to circle left 
Narrow hind limb stance 
Hind foot placement frequently rotated when standing  
Failure to correct left or right hind limb crossover 
placement 
Spontaneous moderately fast tight circling right 
Very reluctant to circle to left 
Side-hopping mild delay left and right hind 






Decreased left ear tone and sensation 
 
Mild narrow hind limb stance 
Slow coordinated rise from lateral recumbency 























Spontaneous moderately tight circling right 
Reluctance to circle left 
Narrow hind limb stance 
Hind foot placement frequently rotated when standing  














Narrow hind limb stance 
Slightly crouched in hind limbs 
Occasional crossing over of hind limbs when circling 
Slow coordinated rise from lateral 
recumbency 
Very mild reduced muscle tone hind limbs 
Repeatable collapse on hindlimb wheelbarrow 
Failure to correct hind limb crossover placement 
Spontaneous moderately tight circling right  
Narrow hind limb stance 
Hind foot placement frequently rotated when standing  
Occasional crossing over of hind limbs when turning 
Occasional overextension of hind and stepping on forelimbs 
Side-hopping mild delay left and right hind 
Decreased hind limb muscle tone 
Control 1 nad nad nad 
Control 2 nad nad nad 
Control 3 nad nad nad 
Control 4 nad Slightly crouched in hind limbs Reluctant to circle to left 
Control 5 nad Occasional mild hind limb bunny hop gait nad 










Possible / very mild left and right hind side-hop delay 
Possible / very mild hind limb wheelbarrow delay 
Left fore flexor withdrawal decreased response 
Control 8 nad nad nad 







3.3.3 Lesion location and volume 
No lesions or evidence of sub-cortical structural abnormalities were visible on the MRI scan of any of 
the sheep prior to surgery or on any of the scans of the eight control sheep after surgery. Of the eight 
QA-lesioned sheep, five had clearly visible bilateral striatal lesions, one had a large lesion in the right 
caudate nucleus and a small lesion in the left caudate nucleus, one had a large right caudate nucleus 
lesion only and one sheep had a small lesion in the left caudate nucleus. Five of the eight sheep 
(QA1, QA5 – QA8) also exhibited cortical hyperintensity with minor accompanying histological 
pathology. In all cases this appeared ipsilateral to the QA-induced striatal lesions and principally in 
the anterior insular cortex with inconsistent involvement of other structures in the frontal and 
temporal lobe.  
The head of the caudate nucleus was the predominant structure lesioned in all sheep, with 
inconsistent involvement of the putamen, ventral striatum and cortex. Table 3.2 shows lesion volume 
and location for individual sheep identified by MRI. Fig. 3.1 shows MRI images of the sheep with the 
largest striatal lesion visible on MRI (QA4), compared to that with the smallest striatal visible lesion 
(QA8). Atrophy of the affected caudate nucleus with concomitant enlargement of the lateral 
ventricle is evident on the final MRI in all lesioned sheep with the morphology of the lateral 











Table 3.2 Location and volume of striatal lesions visible in QA-lesioned sheep using magnetic 
resonance imaging  
ID Side Location¹ Volume of striatal lesion visible  
on MRI (mm³) 
      




QA1 Left VS, IC, GR, Ci 0 0 0 
 
Right CN, P, GR, Ci  985 166 
QA2 Left CN 149 523 6 
 
Right CN  290 31 
QA3 Left CN 199 528 16 
 
Right CN  146 19 
QA4 Left CN, P, VS 484 672 48 
 
Right CN, P, VS  1559 270 
QA5 Left CN, P, VS, IC, GR 861 910 353 
 
Right CN, P, VS, IC  1527 491 
QA6 Left CN 14 40 10 
 
Right CN, P, VS, IC, GR, OF, Sy, Si  522 166 
QA7 Left  CN, P, VS, IC 377 761 118 
 
Right CN, P  830 210 
QA8 Left  CN, VS, IC 10 11 0 
  Right -  0 0 
¹CN: caudate nucleus, P: putamen, VS: ventral striatum, O: olfactory tract and bulb, IC: insular cortex, 
























Figure 3.1 Comparison of the smallest and largest QA lesion by MRI one week after surgery. 
Coronal slice comparing the smallest (A,B, top row, first lesion in the left striatum) with the largest 
QA lesion (C,D, second lesion in the right striatum) one week after lesion surgery. Images in A and C 
are from T1-MPRAGE MRI scans; White arrows point to the hyperintensity of the QA lesion. B and D 
are stylized cartoons of the sections in A and B with the lesions shaded in black / grey. Approximate 
locations of caudate nucleus (CN), putamen (P) and ventral striatum (VS) are indicated in the 
cartoons. The lesion is confined to the CN in the QA8. In QA4, the lesion is visible in the CN, P and VS 
on the right side. There is also some hyperintensity visible in the CN and VS on the left side from the 







































Figure 3.2 Ventricular enlargement is seen after QA lesions. Examples of MRI T1MPRAGE coronal 
slices showing enlargement of the lateral ventricles (white arrows) and corresponding atrophy of the 
caudate nucleus in a QA-lesioned sheep (QA5) with bilateral lesions. Lesions are visible as 
hyperintensity in the caudate nucleus (white arrow heads in lower right image). No change in 
ventricle volume is seen in the matched control saline-treated (Control 6) sheep. Images are taken 
from scans conducted at two time points, pre-surgery and sixteen weeks after the first surgery 



































































Figure 3.3 Morphological change in the caudate nuclei and lateral ventricles of sheep with 
quinolinic acid lesions of the striatum. MRI T1-MPRAGE mid-lesion coronal slice showing 
morphology of the lateral ventricles and caudate nucleus in the sheep with QA lesions of the caudate 
nucleus at four time points: Pre-surgery, one week after the first surgery (left caudate nucleus 
lesioned), five weeks after first surgery (one week after right caudate nucleus lesioned) and sixteen 
weeks after the first surgery. Note that sheep QA1 did not have a MR scan after the first surgery. QA 
lesions are visible as regions of white hyperintensity. Central black regions in each image are the 
lateral ventricles. A representative control sheep is included for comparison. No region of 




















There was no clear relationship between the neurological examination findings and striatal lesion 
size. One sheep with comparatively severe hindlimb dysfunction, evident during both post-surgical 
neurological examinations, had only a small lesion evident on MRI (QA8; Figure 3.1). The sheep with 
upright fetlocks during surgical recovery had the largest bilateral lesions evident on MRI (QA5; Figure 
3.2), yet was one of the least clinically affected sheep on neurological examination. Table 3.3 
provides a subjective ranking of striatal lesion volume per sheep and neurological examination 
findings. There was also no relationship between neurological examination findings and striatal 
lesion location. Two sheep (QA4, QA5) had large bilateral lesions affecting the caudate nucleus, 
putamen and ventral striatum. Despite lesioning of similar structures, their clinical presentation was 
different, with one of the two sheep (QA4) presenting with milder clinical signs during surgical 
recovery yet significantly more clinical findings during the neurological examination. Two sheep 
(QA2, QA3) had caudate nucleus-only lesions on both sides with only one of the two sheep (QA3) 
displaying clinical signs during the unilateral neurological examination. Of the two sheep, the same 
sheep (QA3) displayed significantly more clinical findings during the third neurological examination 
(after both sides had been lesioned). 
 
Table 3.3 Subjective ranking of QA lesion volume and neurological examination severity for 
comparison  






QA1 2 4 
QA2 5 2= 
QA3 4 6 
QA4 7 5 
QA5 8 2= 
QA6 3 1 
QA7 6 7 
QA8 1 8 
1 Subjective ranking: combined lesion volume, 1= smallest, 8=largest; neurological exam, 1=least 




Finally, the veterinary neurological examinations were unable to identify a phenotype associated 
with the cerebral cortex pathology (Fig. 3.4). Lesioning of the striatum was the most important factor 
for the development of clinical signs detectable using a veterinary neurological examination. During 
the neurological examination conducted after the first surgery, four QA-lesioned animals had clinical 
signs detected, with hindlimb dysfunction identified in three of those four animals (QA2, QA3, QA4), 
and decreased ear tone and sensation identified in one animal (QA5). None of the three sheep with 
hind-limb dysfunction had cortical pathology in addition to striatal pathology. QA5 had additional 
cortical pathology, however the clinical signs exhibited by QA5 are consistent with a recognised 
stereotactic frame complication due to the ear bar-induced facial nerve inflammation rather than 
cortical dysfunction. During the neurological examination conducted after the second surgery, clinical 
signs were found in seven out of eight sheep. Three of the five sheep with pathology of the cerebral 
cortex (QA6, QA8, QA5) incurred the lesions during the second surgery (QA5 developed cortical 
pathology after both surgeries, ipsilateral to the surgeries). No clinical signs were detected during the 
neurological examination of QA6. QA8 and QA5 had evidence of hindlimb dysfunction, as seen prior 

































Figure 3.4 Pathology of the cerebral cortex seen in addition to QA lesions of the striatum. Examples 
of MRI T1MPRAGE coronal slices (A,C,E,G,I) from each animal showing hyperintensity of the cerebral 
cortex. Hyperintensity was on the side ipsilateral to the striatal injection site (that is not necessarily 
in the section). The section from each animal were chosen to show the highest intensity of cortical 
hyperintensity. B,D,F,H and are stylized cartoons of the sections with regions of hyperintensity 




















This study evaluated the usefulness of a veterinary neurological examination for identifying and 
characterising clinical signs in sheep with striatal lesions, principally affecting the caudate nucleus. All 
animals had lesions of the striatum while a smaller number showed additional hyperintensity of the 
cerebral cortex. The results suggest that a neurological examination is a reasonable method for 
detection of sheep with bilateral striatal lesions, though it is unreliable for identification of sheep 
with unilateral striatal lesions. The neurological examination was poor at identifying behavioural 
changes relating to rostroventral and rostrolateral cortical pathology and poor at characterising the 
magnitude or extent of striatal or cortical pathology.  
Therapeutic research ideally targets pre-clinical or early-clinical disease phases. We created a 
degree of striatal and cortical pathology that produces a normal-appearing phenotype, unless the 
sheep was interrogated or provoked.  Careful neurological evaluation identified a characteristic 
phenotype associated with bilateral striatal lesions. This consisted of mild hindlimb paresis, mild 
hindlimb proprioceptive deficits and evidence of laterality with either spontaneous or handling-
induced rotation in one direction or reluctance to turn in one direction.  
There were a number of clinical signs identified in control sheep, which may be due to pathology 
associated with the saline infusion or may (more likely) reflect the subjective nature of the veterinary 
neurological examination. Clinically evident unilateral QA-lesioned and bilateral QA-lesioned sheep 
had the same characteristic phenotype, with the phenotype being more pronounced in bilateral-
lesioned sheep. Four sheep frequently rotated one or both hindlimbs when standing. The rotation 
occurred without muscle contracture and appeared to be proprioceptive rather than dystonic. There 
was no evidence of the spontaneous chorea, dyskinesia or dystonia that has been reported in 
primates (Kanazawa et al. 1986, Burns et al. 1995). Spontaneous chorea, dyskinesia and dystonia in 
primates typically resolved over time. Failure to identify these motor abnormalities in sheep during 




examination. Lack of spontaneous chorea, dystonia or dyskinesia in our study may also reflect our 
choice of dose of QA. The investigator (AO’C) selected a dose that would produce sheep with subtle 
symptomology reflecting an early stage of HD (as outlined in Chapter 2.4 and Appendix A), and this 
may not be large enough to cause chorea, dystonia or dyskinesia. 
Two sheep had mild cranial nerve deficits after the unilateral surgery, specifically reduced pinna 
tone. CNVII (the facial nerve) disease can result in reduced pinna tone and can occur secondary to 
middle ear inflammation (de Lahunta and Glass 2009). Pinna tone was normal in these sheep at the 
final neurological examination. The author (AO’C) believes the cranial nerve deficits were a surgical 
complication resulting from ear bar placement and not part of the pathological striatum phenotype 
in sheep. 
Laterality can result from differences in dopamine levels between the two striatae of an individual 
(Zimmerberg et al. 1974). Laterality, either spontaneous or induced, is a variable clinical feature in 
rodents and primates with excitotoxic lesioning of the striatum (Rothman and Glick 1976, Hantraye 
et al. 1990, Kendall et al. 2000). Lower limb motor dysfunction, especially dystonia, has been 
identified in primates with excitotoxic lesions of the striatum (Brouillet et al. 1995, Palfi et al. 1996) 
however paresis of the lower limbs has not been reported previously. Postural deficits are consistent 
with lesions of the extrapyramidal tract and are common in basal ganglia disorders like HD and PD 
(Salomonczyk et al. 2010, Erro and Stamelou 2017).  
The neurological examination was an unreliable modality for detection of unilateral striatal 
lesions with clinical signs detected in only four out of eight sheep after unilateral surgery, despite 
lesions being evident on MRI. The difficulty of unilateral striatal lesion detection in sheep is 
consistent with other species: NHPs typically appeared unaffected or display mild, transient clinical 
signs following unilateral excitotoxic lesioning (Kanazawa et al. 1986, Hantraye et al. 1990, Burns et 




unilateral QA lesions of the striatum required sophisticated quantitative behavioural tests principally 
involving complex reaching tasks (Whishaw et al. 2007, Klein et al. 2013) for reliable detection.  
Rodents and primates display bilaterality in their extrapyramidal pathways with approximately 10-
20% of basal ganglia output neurons projecting to the contralateral thalamus (Hazrati and Parent 
1991, Christensen et al. 1999). The crossover of basal ganglia output neurons allows the unaffected 
basal ganglia to compensate for and mask clinical symptomology following a unilateral striatum 
lesion (Kellinghaus et al. 2003). While the bilaterality of extrapyramidal pathways in sheep is 
unknown, the assumption of crossover in the efferent pathways of the basal ganglia of sheep, as in 
rodents and primates, would mean the unaffected basal ganglia could compensate for and mask 
unilateral striatal lesions, potentially necessitating a more sensitive method of detection of striatally 
related neurological dysfunction than allowed by the veterinary neurological examination used in this 
study. The neurological examination detected all sheep with well developed bilateral lesions evident 
on MRI, though no clinical signs were detected in the sheep that had a large lesion in the right 
caudate nucleus and a small lesion in the left caudate nucleus. The ability of the neurological clinical 
examination to detect bilateral striatum lesions likely reflects a loss of bilateral pathway 
compensation.  
Due to the difficulty associated with stereotactic placement in the sheep brain (van der Bom et al. 
2013), delivery of QA to and pathology of extra-striatal sites was anticipated, as occurs in similar 
primate studies (Burns et al. 1995, Kendall et al. 2000, Clarke et al. 2008). The inability of the 
neurological examination to detect cortical pathology in the QA-lesioned sheep likely reflects the 
exact structures lesioned, the mainly unilateral nature of the cortical pathology, associated plasticity 
of the brain following injury (Kou and Iraji 2014, Dall'Acqua et al. 2017) and the motor bias of the 
veterinary neurological examination. The anterior insular cortex was the principal cortical structure 
lesioned in those sheep with cortical pathology, with variable lesioning of the gyrus rectus, orbital-




cortex. These cortices have a wide range of prescribed functions (Meyer et al. 2005, Apps and 
Ramnani 2014, Leonard et al. 2016, Gogolla 2017, Rudebeck et al. 2017, Schneider and Koenigs 
2017), however they tend to be non-motor functions. The primary motor cortex is located within the 
frontal lobe, medial and posterior to the structures lesioned (Johnson et al. 2019). 
The relationship between the proportion of a sheep’s total striatal area that was-lesioned and the 
associated symptomology was poor, even in bilaterally-lesioned sheep. For example, one sheep had 
the largest lesion in both the left and right striatum yet was one of the least clinically affected of the 
bilaterally-lesioned sheep, while another sheep with similar sized lesions displayed marked laterality 
and evidence of hind limb paresis. NHP studies have found that the association between lesion size 
and clinical signs is also not straightforward and that very large lesions involving 60% of the striatum 
or greater can paradoxically be associated with less choreic movement than smaller lesions 
(Kanazawa et al. 1990). The four week delay between the left and right striatal lesions may have 
allowed resolution of acute reversible neuropathology on one side at the time of second lesion and 
the opportunity for brain plasticity mechanisms to reduce symptomology (Chen et al. 2010, Buch et 
al. 2017).  
The region of the striatum consistently lesioned was the head of the caudate nucleus, with 
inconsistent involvement of the putamen and ventral striatum. No association was identified 
between lesion location and the clinical profile. NHP studies have found that lesion location is 
important for the development of dyskinesia and rotational behaviour in primates, with putamen 
lesions associated with motor dysfunction (Burns et al. 1995, Kendall et al. 2000). Assuming sheep 
display similar topographical regionality as primates, more extensive lesioning of the sheep putamen 
may result in a greater range and severity of clinical signs detectable by neurological examination. 
Notably, the topography of the striatum is heterogeneous and includes a large number of functional 




striatae may impact different functional sub-divisions, potentially resulting in different 
symptomology. 
3.5 Conclusion 
In summary, this study evaluated the use of a veterinary neurological examination as a method of 
phenotype identification and pathology characterisation in sheep with significant excitotoxic lesions 
of the striatum and cortex, principally affecting the caudate nucleus of the striatum. A phenotype 
was identified consisting of mild hindlimb motor dysfunction and laterality, however the diagnostic 
sensitivity of the veterinary neurological examination was moderate. The phenotype appeared to be 
associated with the striatal lesions, with it being more evident after bilateral striatal lesioning. 
Characterisation of the proportion or region of the striatum and cortex lesioned was not possible in 
this study using a standard veterinary neurological examination. To ensure we can comprehensively 
evaluate striatal symptomology and pathology in sheep, more specific neurological tests of striatal 
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This chapter investigates the consequences of QA-induced striatal pathology in sheep on rotational 
behaviour and performance in discrimination learning tasks. Two surgeries were performed, four 
weeks apart, on sixteen sheep. During the first surgery, QA (180 mM in 75µl) or the same volume of 
saline was infused into the left striatum; during the second surgery, the same treatment (QA or 
saline) was infused into the right striatum. Rotation studies were performed pre-surgically, ten days, 
three weeks and sixteen weeks after the first surgery. Two-choice discrimination learning was 
assessed in a novel apparatus twelve weeks after the first surgery. A directional bias was evident 
three weeks (unilateral lesion) and sixteen weeks (bilateral lesions) after the first surgery in the QA-
lesioned sheep, when compared to the saline-treated sheep. However, the direction and magnitude 
of bias in individual sheep at any one timepoint varied markedly, making identification of QA-
lesioned individuals difficult. No association was observed between net rotation and lesion 
characteristics. There was no difference between saline-treated and QA-lesioned sheep in their 
ability to learn the acquisition and reversal phases of the two-choice discrimination learning task. 
These results indicate that rotation studies are a more sensitive technique than two-choice 
discrimination learning tasks for identification of striatal lesions in sheep. However, alternative 
techniques to those investigated in this study are required in sheep to identify and characterise 
striatal lesions comprehensively. Excitotoxic lesioning of the sheep striatum produces a variable 
phenotype, consistent with HD patient symptomology. Further research is required to establish the 
relationship between lesion characteristics and phenotype. 
4.2 Background 
Locomotor activity abnormalities and discrimination task deficits have been demonstrated in QA-
lesioned rodents (Ayalon et al. 2004, Giorgetto et al. 2015, Morales-Martinez et al. 2017) and NHPs 
(Clarke et al. 2008). Measuring the magnitude and direction of net rotation, or directional bias, in 




characterising striatal lesions in rodents (Ungerstedt and Arbuthnott 1970, Hudson et al. 1993) 
although lesion size and location is important (Norman et al. 1992, Fricker et al. 1996) and results are 
variable in NHPs (Kendall et al. 2000). Sheep are capable of striatal dependent two-choice 
discrimination tasks (Morton and Avanzo 2011), however the effect of brain lesion(s) on 
discrimination learning in sheep has not been determined previously.  
The first aim of this study was to describe a technique for performing dopamine agonist mediated 
rotation studies in sheep. The second aim of this study was to investigate the ability of dopamine 
agonist mediated rotation studies to identify and characterise striatal pathology in QA-lesioned 
sheep. The third aim was to perform two-choice discrimination tasks in the QA-lesioned sheep to 
determine if they have cognitive decline. The studies expand our understanding of the phenotypic 
consequences of lesioning the sheep striatum with QA and further develop the toolkit for assessing 
striatal lesions in sheep.  
4.3 Results 
4.3.1 Rotation 
At three weeks after the first surgery, net rotation in response to apomorphine was significantly 
greater in QA-lesioned than in saline-treated (p = 0.04; Fig. 4.1C) or pre-surgical control sheep (p < 
0.01; Fig. 4.2B), indicating that the QA-lesioned sheep showed a propensity to rotate more in one 
direction. Table 4.1 shows the mean rotation for the QA-lesioned and saline-treated sheep at each 
timepoint. There was no difference in apomorphine-induced net rotation between QA-lesioned, 
saline-treated or pre-surgical control sheep ten days after the first surgery (p = 0.11; Fig. 4.1A,B and 
Fig. 4.2).  
However, there was an appreciable increase in the spread of QA-lesioned individual sheep 
responses after apomorphine, compared to saline-treated sheep (Fig. 4.1B). Interestingly, 
apomorphine-induced net rotation was significantly increased in QA-lesioned sheep sixteen weeks 




control (p < 0.01; Fig. 4.2B) sheep, indicating that, despite a lesion in the contralateral striatum, a 
directional bias still existed in the QA-lesioned sheep with mature lesions. 
 
Table 4.1 Mean net rotation for each time period for saline-treated and QA-lesioned sheep 
Treatment Group Time Period Number of rotations 95% Confidence Interval 
  




Saline-treated  Pre-surgical 16±10 -6 38 
 Ten days 31±28 -28 91 
 Three weeks 28±37 -51 108 
 Three months 26±26 -30 82 
     
QA-lesioned  Pre-surgical 27±10 5 49 
 Ten days 99±28 39 158 
 Three weeks 146±37 67 226 
  Three months 107±26 51 163 






Figure 4.1 A-B Net rotational activity in saline-treated and quinolinic acid-lesioned sheep. Net 
anticlockwise rotation (ipsilateral to the first surgery) is shown as a positive, net clockwise rotation 
(contralateral to the first surgery) as a negative. Net rotation measured in the 60 minutes 
immediately prior (0) to apomorphine (Apo) administration and for 60 minutes immediately after 0.1 
mg/kg apomorphine hydrochloride (+) is administered. Data are shown from testing pre-surgically (A) 







Figure 4.1 C-D Net rotational activity in saline-treated and quinolinic acid-lesioned sheep. Net 
anticlockwise rotation (ipsilateral to the first surgery) is shown as a positive, net clockwise rotation 
(contralateral to the first surgery) as a negative. Net rotation measured in the 60 minutes 
immediately prior (0) to apomorphine (Apo) administration and for 60 minutes immediately after 0.1 
mg/kg apomorphine hydrochloride (+) is administered. Data are shown from testing three weeks 
after the first surgery (C) and sixteen weeks after the first surgery (D). Individual QA-lesioned sheep 






Figure 4.2 Mean net rotation in saline-treated and quinolinic acid-lesioned sheep. Mean pre-
surgical net rotation (Pre-) is compared with mean post-surgical net rotation at three time points, ten 
days (10d) after the first surgery, three weeks (3w) after the first surgery and sixteen weeks (16w) 
after the first surgery in (A) saline-treated and (B) QA-lesioned sheep. Data are mean + SD. * p < 0.05 







There was no clear relationship between the lesion location or volume (Table 4.2) and magnitude 
or direction of net rotation. For example, QA1, who had a large lesion of the caudate nucleus and 
putamen on the right side, displayed no directional bias (Fig. 4.1B-D). QA3, with a medium sized 
lesion of the caudate nucleus on both sides, showed little directional bias ten days after the first 
surgery then a large ipsilateral bias in direction three weeks after the first surgery which was 
maintained sixteen weeks after the first surgery (Fig. 4.1B-D). QA2, who had similar lesions, in size 
and placement, to QA3, showed subdued directional ipsilateral bias at three weeks after the first 
surgery, compared to QA3, and a smaller directional bias at sixteen weeks after the first surgery (Fig. 
4.1C-D). QA6 had a small lesion of the caudate nucleus after the first surgery, yet had a larger 
directional bias than QA2 and QA3 at ten days and in the opposite direction, with a decrease in 
magnitude of net rotation at three weeks and sixteen weeks (Fig. 4.1B-D). QA4 and QA5, with a large 
lesion of the caudate nucleus, putamen and ventral striatum on both sides, showed modest 
ipsilateral rotational activity at ten days and three weeks after the first surgery (Fig. 4.1B-C). QA5 
showed little directional bias at sixteen weeks after the first surgery while QA4 showed a large 
contralateral bias in net rotation at sixteen weeks (Fig. 4.1D). There was no difference in rotation 
between sheep with and without lesions of the cerebral cortex (p = 0.38). 
The primary investigator correctly predicted 5 / 8 QA-lesioned sheep and 0 / 8 of the control 
sheep as ‘likely to be QA-lesioned’ based on net rotation. Five of the eight saline-treated sheep were 
correctly predicted as saline-treated; however, one QA-lesioned sheep was predicted to be saline-
treated. Three saline-treated sheep and two QA-lesioned sheep were unable to be subjectively 








Table 4.2 Lesion characteristics and subjective prediction of experimental group 




QA1  Left VS, IC, GR, Ci n/a 
Saline 
 Right CN, P, GR, Ci Large 
QA2  Left CN Medium 
QA 
 Right CN Medium 
QA3  Left CN Medium 
QA 
 Right CN Medium 
QA4  Left CN, P, VS Large 
QA 
 Right CN, P, VS Large 
QA5  Left CN, P, VS, IC, GR Large  
Unsure 
 Right CN, P, VS, IC Large 
QA6  Left CN Small 
Unsure 
 Right CN, P, VS, IC, GR, OF, Sy, Si Medium 
QA7  Left  CN, P, VS, IC Large 
QA 
 Right CN, P Large 
QA8  Left  CN, VS, IC Small 
QA 
 Right None n/a 
Control 1 Left None n/a 
Saline 
 Right None n/a 
Control 2 Left None n/a 
Saline 
 Right None n/a 
Control 3 Left None n/a 
Saline 
 Right None n/a 
Control 4 Left None n/a 
Saline 
 Right None n/a 
Control 5 Left None n/a 
Unsure 
 Right None n/a 
Control 6 Left None n/a 
Unsure 
 Right None n/a 
Control 7 Left  None n/a 
Unsure 
 Right None n/a 
Control 8 Left  None n/a 
Saline 
 Right None n/a 
¹CN: caudate nucleus, P: putamen, VS: ventral striatum, O: olfactory tract and bulb, IC: insular cortex, 
GR: gyrus rectus, Ci: cingulate gyrus, OF: orbital-frontal gyrus, Sy: sylvian gyrus, Si: sygmoideus gyrus. 
²Based on data detailed in Chapter 3, Table 3.2 and Section 3.3.3. ³Small <100mm; Medium 100-




4.3.2 Simple two-choice discrimination learning task 
All sheep learned the acquisition and reversal phases of the simple two-choice discrimination 
learning task. When saline-treated and QA-lesioned sheep were compared by number of sessions 
required to reach a criterion of two consecutive sessions of 80% or greater correct, there was no 
difference between saline-treated and QA-lesioned sheep for the acquisition (saline-treated cohort: 
6.6 ± 1.9 sessions, QA-lesioned cohort: 7.2 ± 2.2 sessions, p = 0.55) or the reversal (saline-treated 
cohort: 10.1 ± 1.6 sessions, QA-lesioned cohort: 10.4 ± 4.1 sessions, p = 0.88). Retrospective analysis 
was performed using a different criterion of six discriminations correct in a row. When using this 
criterion, number of trials were compared instead of number of sessions. Using this criterion, there 
was still no significant difference for either the acquisition (saline-treated cohort: 52 ± 15 trials, QA-
lesioned cohort: 57 ± 18 trials, p = 0.54) or the reversal (saline-treated cohort: 79 ± 14 trials, QA-
lesioned cohort: 92 ± 37 trials, p = 0.41: Fig. 4.3).   
There was no discernible association between lesion location or volume (Table 4.2) and the ability 
of the sheep to learn to discriminate. For example, the first sheep to reach criterion for the reversal, 
QA3, had bilateral caudate nucleus lesions, while QA2, that also exhibited bilateral caudate nucleus 
lesions, was the slowest animal to reach reversal criterion. QA6, with a small lesion in the left 
striatum and medium lesion in the right striatum reached reversal criterion in 69 trials, compared 
with QA7, with two large striatal lesions, that reached reversal criterion in 70 trials.  
Where there were sheep with concomitant cerebral cortex pathology, the cerebral cortex damage 
did not appear to influence the performance of the QA-lesioned sheep, when compared to the sheep 
with striatal lesions only, in the acquisition (p = 0.82) or the reversal (p = 0.43). QA2, that was much 
slower to achieve reversal criterion compared to any other sheep, did not exhibit any cerebral cortex 
pathology. In contrast both QA6 and QA7, that reached reversal criterion as quickly as the fastest 




There was no correlation between rotational behaviour and two-choice discrimination learning 
performance. While QA2 (the slowest sheep out of either experimental group to reach criterion in 
either analysis), was correctly predicted to be QA-lesioned based on rotational data, QA3 (also 
correctly predicted to be a QA-lesioned sheep), reached reversal criterion quickest out of both 
cohorts. Another sheep correctly predicted to be QA-lesioned, QA7, reached reversal criterion in the 
same number of trials as the fastest saline-treated sheep.  
 
 
Figure 4.3 Simple two-choice discrimination learning in saline-treated and quinolinic acid-lesioned 
sheep. The mean (± SD) and individual number of trials required to reach a criterion of six correct 
choices in a row for saline-treated (Saline) and QA-lesioned sheep (QA) during acquisition (Acq) and 










This study evaluated rotational activity and executive decision-making capability in sheep with QA-
induced primary striatal and secondary cerebral cortex lesions. An experimental sheep model with 
bilateral striatal lesions has not been created previously. Loss of cognitive adaptability and altered 
motor behaviours are a feature of many neurodegenerative conditions, including HD (Roos 2010), 
and are associated with striatal and cortical lesions in rodents and NHPs (Roitberg et al. 2002, Clarke 
et al. 2008, Lindgren et al. 2013, Mishra and Kumar 2014). Results in this study indicate that while net 
rotation in a cohort of sheep with lesions of the striatum is significantly different to that of saline-
treated sheep, there is substantial individual variation in rotational activity. Neither unequivocal 
identification of lesioned sheep nor characterisation of the size / locations their lesions was possible 
using rotation studies. Two-choice discrimination learning tasks were also unable to distinguish QA-
lesioned sheep from saline-treated sheep. Sheep with excitotoxic lesions of the striatum and cerebral 
cortex have variable phenotypes requiring more sophisticated techniques for identification and 
characterisation of their lesions than those used in this study. 
Apomorphine-induced rotational activity in the QA-lesioned sheep cohort after the first surgery is 
consistent with rodent and NHP unilateral striatum lesion studies (Jerussi and Glick 1975, Hantraye et 
al. 1990, Giorgetto et al. 2015). However, the marked variability in rotation is in contrast to that seen 
in rodents where rotation is predictable (Jerussi and Glick 1975, Antunes et al. 2013) and more 
similar to NHPs (Burns et al. 1995). Following infusion of QA into the striatum of rodents, there is a 
range of cellular, neurochemical and receptor changes that occur over an extended time course, with 
loss of vulnerable neurons within twenty four hours, loss of GABAA receptors at seven days and 
marked astrocytosis evident at one to four weeks (Brickell et al. 1999). A study which conducted 
longitudinal measurements of apomorphine-induced rotational activity in QA-lesioned rodents found 
the magnitude of the net rotational response increased until one month post-lesioning (Shemesh et 




have produced cellular, neurochemical and receptor changes that would result in a significant 
measurable difference in net rotation. 
Apomorphine-induced rotational activity in the QA-lesioned sheep after the second surgery was 
also significantly increased compared to saline-treated and pre-surgical control sheep. Lesion 
variation in this study is likely to underlie the rotation seen after the second surgery, as an imbalance 
in dopamine signalling between two non-identical lesions would likely exist. The sixteen weeks post-
lesion rotation studies provided evidence that at least one lesion from the two surgeries produced a 
measurable behavioural effect. It is possible that the first surgical lesion had resolved by the sixteen 
week rotation study, such that the sheep was not functionally lesioned on both sides. However, 
evidence of motor deficits and immunohistochemical changes have been found in NHPs with chronic 
unilateral and bilateral QA-induced striatal lesions up-to nine months’ post-surgery (Ferrante et al. 
1993, Kendall et al. 2000, Roitberg et al. 2002). In the final MRI, the QA-lesioned sheep exhibited 
striatal atrophy and ventricular dilation on the left as well as the right side. Assuming the time-course 
of QA lesion resolution in sheep is similar to that of NHPs, then it is likely that the lesions from the 
first surgery, as well as the second surgery, are still influencing the measurement of a behavioural 
effect at the three-month rotation study, performed after the completion of the two-choice 
discrimination learning tasks.  
While the magnitude of rotation in one direction was significantly greater in the QA-lesioned 
cohort compared to the control cohort, the direction and magnitude of individual animal rotation 
varied markedly amongst QA-lesioned sheep. Despite reviewing data from multiple time-points, the 
investigator correctly predicted the experimental group for only 5 / 8 of the sheep, which is not 
different to chance. Phenotypic variability between animals in response to dopaminergic agonists is 
also seen in NHPs with striatal lesions (Kanazawa et al. 1990, Burns et al. 1995). In those studies, the 
magnitude and direction of post-operative net rotation before and after dopamine agonists was 




preference, as well as lesion size and location within a heterogeneous striatum and the inherent 
propensity of an individual to rotate (Jerussi and Glick 1975, Norman et al. 1992, Hudson et al. 1993, 
Fricker et al. 1996, Kendall et al. 2000, Ogawa et al. 2018). In our study, no association was observed 
between rotation activity and lesion volume or location, which likely reflects the individual variation 
in propensity to rotate and the variation in lesion size and location. The lack of effect of the cerebral 
cortex pathology on rotation is consistent with the dopamine agonist potentiated differences in 
striatal dopaminergic signalling causing the rotation observed (Molochnikov and Cohen 2014).  
We had predicted that the QA-lesioned sheep would have difficulty learning the reversal phase of 
the simple two-choice discrimination learning task. However, all sheep learnt both the acquisition 
and the reversal. One QA-lesioned sheep (QA2) was considerably slower than the rest of the lesioned 
sheep to learn the reversal, yet learned the acquisition without apparent difficulty. While this may 
reflect a reversal learning impairment due to the QA lesion, because it is a single animal this 
conclusion cannot be justified. 
Discrimination learning, particularly reversal learning, is impaired in rodents (Ayalon et al. 2004, 
Castane et al. 2010) and NHPs (Dias et al. 1996, Clarke et al. 2008) with striatal and cerebral cortex 
lesions. The failure to detect a reversal learning deficit in the QA-lesioned sheep in this study does 
not provide conclusive evidence that sheep with caudate and cerebral cortex lesions do not develop 
reverse learning deficits. The QA lesions affecting the pre-frontal cortex were confined to one 
hemisphere. Behavioural studies in NHPs have shown that unilateral pre-frontal cortex lesions have 
no cognitive impact; bilateral lesions are required to initiate cognitive deficits and difficulty with 
reversal learning (Gaffan and Wilson 2008). Furthermore, it is possible that there was sufficient 
neuronal recovery in the QA-lesioned cohort at the beginning of discrimination testing to improve 
performance and nullify any difference between QA-lesioned and saline-treated sheep. Chronic 
recovery of impaired, but not dead, neurons, with a correlated improvement in behavioural tests, 




striatum is consistently visible on anatomical MRI of sheep with QA lesions of the striatae, and that 
there is a measurable behavioural effect, using rotation studies, after discrimination testing is 
finished. This indicates that rotation studies, which utilise pharmacological intervention, are a more 
sensitive method than two-choice discrimination learning tasks for detecting striatal lesions in sheep 
with additional heterogeneous pathology of the cerebral cortex, but neither is adequate for assessing 
the consequences of striatal lesions.  
4.5 Conclusion 
In conclusion, excitotoxic lesions of the striatum can induce measurable behavioural effects in sheep, 
highlighting the potential usefulness of this species for studying the behavioural sequelae of 
neurodegeneration. More sophisticated techniques are required however, for comprehensive 
identification and characterisation of striatal lesions in sheep. While rotation studies are a more 
sensitive technique than two-choice discrimination learning tasks for the identification of striatal 
lesions in sheep, neither technique unmasked all individuals with lesions or provided any 
characterisation of a lesion. The development of variable symptomology in sheep following QA-
lesioning is consistent with the variable symptomology of HD patients, however more research needs 
to be done to permit accurate and precise lesioning to occur and to understand the similarities and 
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This chapter describes the use of MRS and DTI to investigate in vivo metabolic and structural changes 
in sheep following QA-lesioning of the striatum. Sixteen sheep received a bolus infusion of QA (75 µl, 
180 mM) or saline, first into the left striatum and then four weeks later into the right striatum. MRS 
and DTI of the striatae was performed at four timepoints: pre-surgery, one week after the first 
surgery, five weeks after the first surgery and sixteen weeks after the first surgery. A linear mixed 
effects model was used to compare acute (one week after surgery) and chronic changes (five weeks 
or greater after surgery) in metabolite concentrations and FA of QA-lesioned striatae compared with 
unlesioned and saline-treated striatae. Compared to unlesioned or saline-treated striatae, there was 
a significant decrease in the neuronal marker NAA and in FA in acutely-lesioned striatae of the QA-
lesioned sheep, followed by a recovery of NAA and FA in the chronically-lesioned striatae. NAA level 
changes indicate acute death and / or impairment of neurons immediately after surgery, with 
recovery of reversibly-impaired neurons over time. The change in FA values of the QA-lesioned 
striatae are consistent with acute structural disruption, followed by reorganisation and glial cell 
infiltration with time. Immunohistochemical examination of the chronic lesion supported the MRS 
and DTI changes, showing heterogeneous neuronal loss and gliosis visible in the QA-lesioned striatae. 
The study demonstrates that MRS and DTI changes in QA-sheep are consistent with HD-like 
pathology in other species and that the MR investigations can be performed in sheep using a 
clinically relevant human MRI scanner. 
5.2 Background 
A small number of QA-lesioned rodent studies have assessed lesion development with MRS and 
DTI, performed on very high magnetic field strength MRI scanners (Sauer et al. 1992, Strauss et al. 
1997, Tkac et al. 2001, Shemesh et al. 2010). MRS is used to detect changes in the concentration of 
metabolites in vivo (Tognarelli et al. 2015). DTI is used to detect in vivo microstructural changes and 




2013, Lope-Piedrafita 2018). FA is a measure of DTI (Alexander et al. 2007). MRS and DTI have not 
previously been performed in an excitotoxic large animal model. DTI and spectroscopic investigation 
of the normal adult sheep brain have been performed previously (Lee et al. 2015b, Gray-Edwards et 
al. 2018) but without a longitudinal component. Unlike post mortem techniques for tissue analysis, in 
vivo MR modalities, including DTI and MRS, allow the correlation of structural, functional and 
biochemical changes over time without having to kill study animals, or use isotopic labelling. The aim 
of this study was to use longitudinal MRS and DTI to assess lesion development and gross 
pathological change in a translational excitotoxic sheep model of HD, performed on a clinically 
relevant 3-Tesla MR scanner. 
5.3 Results 
5.3.1 Magnetic resonance spectroscopy  
In the acutely-lesioned condition, there were significant decreases in NAA (p < 0.001), TNAA (p < 
0.001) and total creatine (p <0.001) in the QA-lesioned compared to both the saline-treated and 
unlesioned striatae. An example spectrum is shown in Fig. 5.1. Additionally, there was also a 
significant decrease in myo-inositol (p = 0.028) in the QA-lesioned striatae compared to the 
unlesioned striatae. Metabolite concentrations did not differ between the acute saline-treated 
striatae and unlesioned striatae (Table 5.1).  
In the chronically-lesioned condition, there was no difference in metabolite concentrations 
between QA-lesioned and saline-treated striatae (Table 5.1). When chronic changes are compared 
with unlesioned striatae, NAA was significantly reduced in both saline (p = 0.019) and QA-lesioned 
striatae (p = 0.011). Myo-inositol was significantly increased in chronically lesioned QA-striatae 







Table 5.1 Mean metabolite concentration in control and quinolinic acid lesioned striatae, 
measured using magnetic resonance spectroscopy 
Metabolite Metabolite concentration (mM) mean ± SEM 
 Pre-surgical  Saline  QA 
      1 week 5 - 16 weeks   1 week 5 - 16 weeks 
NAA 5.52 ± 0.28  5.01 ± 0.49 4.32 ± 0.39  2.24 ± 0.51 4.30 ± 0.39 
TNAA 6.38 ± 0.28  6.42 ± 0.49 5.81 ± 0.36  3.44 ± 0.51 6.15 ± 0.39 
Gln 4.50 ± 0.55  3.31 ± 0.57 2.93 ± 0.66  3.63 ± 0.80 4.20 ± 0.67 
Glu 6.62 ± 0.60  5.24 ± 0.99 5.99 ± 0.77  4.79 ± 0.95 6.89 ± 0.75 
Ins 9.48 ± 0.55  8.96 ± 0.93 9.14 ± 0.70  7.03 ± 0.97 10.15 ± 0.76 
TCr 7.86 ± 0.28  8.42 ± 0.50 7.63 ± 0.36  5.85 ± 0.52 8.08 ± 0.40 
TCho 2.83 ± 0.14   3.10 ± 0.22 2.96 ± 0.18   2.67 ± 0.23 2.79 ± 0.19 
NAA: N-acetylaspartate, TNAA: N-acetylaspartate and N-acetylaspartylglutamate, Gln: glutamine, 
Glu: glutamate, Ins: myo-inositol, TCho: glycerophosphocholine and phosphocholine, TCr: creatine 
and phosphocreatine. # (p < 0.05) compared to pre-surgical mean. *(p < 0.05) compared to saline-











Figure 5.1 Comparison of the magnetic resonance spectra from a representative sheep after 
lesioning the left striatum with quinolinic acid. Spectra are from (A) the unlesioned right striatum 
and (B) the QA-lesioned left striatum one week after the first surgery. Arrows in B indicate significant 
changes in the corresponding metabolites labelled in A. Glutamine (Gln), glutamate (Glu), myo-
inositol (Ins), N-acetylaspartate (NAA), N-acetylaspartylglutamate (NAAG), glycerophosphocholine 





5.3.2 Diffusor tensor imaging and fractional anisotropy  
Qualitative inspection of directional DTI maps revealed an apparent reduction in the size and 
integrity of fibre tracts in acute QA-lesioned (Fig. 5.2 D,F) compared to saline-treated (Fig. 5.2 C,E) or 
unlesioned striatae. By contrast, there was no visible difference in the fibre tracts of the chronically 
lesioned striatae and matching saline-treated or unlesioned striatae (Fig. 5.2 G,H). 
FA values were significantly decreased in acutely-lesioned compared to unlesioned (p < 0.001) 
and matching saline-treated (p < 0.001) striatae. FA values in chronically-lesioned striatae were 
significantly increased compared to those in unlesioned (p < 0.001) or matching saline-treated (p < 
0.001) striatae. There was no difference between the FA values of control (unlesioned and saline-
treated) striatae at any timepoint (Table 5.2).  
 
Table 5.2 Mean fractional anisotropy values in QA-lesioned and saline-treated sheep striatae: pre-
surgery, one week after surgery (acute lesion) and five to sixteen weeks after surgery (chronic 
lesion) 
Experimental group FA × 10-6 mm2/s 










Pre-surgical 320 ± 8 304 335 
Saline (1 week) 327 ± 13 301 354 
QA (1 week) 170 ± 11*# 144 196 
Saline (5-16 weeks) 317 ± 13 296 338 
QA (5-16 weeks) 396 ± 10 *# 374 419 
*p < 0.05 compared to saline-treated mean 























Figure 5.2 Comparison of diffusion tracts in saline-treated and quinolinic acid-lesioned sheep after 
surgery. Coronal images showing a brain slice through the caudate nucleus (CN) and putamen of two 
sheep. Diffusion tracts in a saline-treated (A,C,E,G) and a QA-lesioned (B,D,F,H) sheep are shown 
from MRI 2 (one week after the first surgery; A,B,C,D), MRI 3 (five weeks after the first surgery; E,F), 
and MRI 4 (sixteen weeks after the first surgery; G,H). Magnetic resonance images are T1-MPRAGE 
scans with diffusion tracts overlaid. Cartoons in (A) and (B) are stylized images of the scan 
immediately below, with the tracts shaded in dark grey. The diffusion tracts in the MRI scans are in 
colour (rainbow scale). The location of the caudate nucleus (CN), corpus callosum (CC) and a right-
side control sheep diffusion tract (T) are indicated in (A). The QA-induced visible CN lesion is shaded 
in light grey (x) in (B), and a black arrowhead indicates a reduced tract on the left side. Diffusion 
tensor tracts are visibly disrupted (white arrowheads in D,F) in the striatae of QA-lesioned sheep on 
the left side in MRI 2 (D), then the right side in MRI 3 (F). By MRI 4 (H), the disruptions (*) to the 























Examination of the haematoxylin and eosin stained sections of the caudate nucleus of the saline-
treated sheep (Fig. 5.3A) revealed an even dispersion of neurons and glial cells within the neuropil of 
the striatum. Neurons appeared normal, with a high nucleus to cytoplasmic ratio, nuclei being round 
to ovoid in shape with a prominent nucleolus and even dispersion of chromatin clumps throughout 
the nucleoplasm (insert in Fig. 5.3A). A variable but moderate sized, lightly basophilic to amphophilic 
cytoplasm surrounded the nucleus. Neurons were approximately 15 µm in size, though an occasional 
neuron was disproportionately larger in size than the average neuron. 
By contrast, the neuropil at the site of infusion in the caudate nucleus of each of the QA-lesioned 
sheep had a high density of nuclei (neuronal and glial) in the haematoxylin and eosin stained sections 
of the striatum (Fig. 5.3B). Traversing axons of the internal capsule were intact, as were microvessels 
(Fig. 5.3B). Examination of the nuclei dense region revealed a core with central necrosis of most 
cellular elements and occasional vacuolation of the neuropil. Immediately surrounding the necrosis 
was an area with marked gliosis (Fig. 5.3 B,D,F). This area was devoid of neurons. A penumbra with a 
gradation of heterogeneous neuronal damage and gliosis extended out from the core. A small 
number of neurons within the penumbra were preserved (Fig. 5.3B), however the majority displayed 
evidence of damage that ranged from moderate shrinkage and increased basophilic staining of the 
cytoplasm with a normal looking nucleus though to marked shrinkage of the cytoplasm with small 
hyperchromatic, pyknotic or karyolitic nuclei (Fig. 5.3B).  
GFAP and Iba1 immunohistochemistry confirmed gliosis of the highly cellular regions in the QA-
lesioned sheep (Fig. 5.3 D,F). QA lesions were evident as a darker stained area on gross examination 
of Iba1 slides, while microscopic examination revealed a large number of microglia (Fig. 5.3D). 
Compared to the staining observed in saline-treated sheep (Fig. 5.3E), GFAP staining of the QA-
lesioned striatum (Fig. 5.3F) revealed astrogliosis with increased perinuclear staining of astrocytes 























Figure 5.3 Histology of the striate in representative saline-treated and quinolinic acid-lesioned 
sheep. Haematoxylin and eosin (H&E; A,B), Iba1 (C,D) and GFAP (E,F) staining of saline-treated 
striatae (A,C,E) and QA-lesioned striatae (B,D,F). In both (A) and the insert in (A), there are numerous 
neurons (examples are indicated by the white arrows) and low cellularity of the neuropil, compared 
to (B) which is highly cellular, with intact traversing axon bundles (white arrow) and blood vessels 
(white arrow heads). The insert in (B) shows a spared neuron (white arrow) amongst glial cells and 
degenerate neurons (white arrow heads). In contrast to (C), there are numerous microglia (examples 
are indicated by the white arrows) visible in (D). The astroglia in (E) are not reactive, in comparison 
with (F) where the astroglia have short, thick processes (examples are indicated by the white 




















This study demonstrates for the first time with MRS and DTI, a natural history of changes that occur 
in vivo following infusion of QA in the sheep striatum to create an excitotoxic model of HD. As 3-Tesla 
MR scanners are routinely used for scanning human brain, demonstrating pathological changes in 
QA-lesioned sheep brain with this technology highlights the clinical relevance of this species for 
modelling neurodegenerative disease.  
NAA, a nervous system-specific metabolite, is considered to be a marker of neuronal viability 
(Moffett et al. 2007). Decreases in NAA are thought to reflect neuronal dysfunction (Demougeot et 
al. 2001) and have been correlated with caudate atrophy in HD (Padowski et al. 2014). The changes in 
the QA-lesioned sheep striatae are consistent with those reported for QA-lesioned rodent striatae, 
with a reduction in NAA after QA infusion (Strauss et al. 1997, Tkac et al. 2001, Shemesh et al. 2010), 
followed by  longer term partial recovery of NAA levels (Shemesh et al. 2010). Shamesh et al (2010) 
found that after lesioning the rodent striatum with QA, the majority of striatal neurons had been 
reversibly impaired whilst only a smaller number had undergone cell death. A similar mechanism of 
cell death or reversible impairment of neurons would explain the incomplete recovery of NAA in the 
chronically-lesioned striatae in the QA-lesioned sheep. Reduced NAA has also been observed in HD 
monkeys (Chan et al. 2015) and reversible impairment of striatal neurons with spontaneous partial 
recovery was identified in both rodents and NHPs following withdrawal of the mitochondrial toxin, 3-
NP, using longitudinal MRS and immunohistochemistry (Dautry et al. 2000).  
TNAA shows a similar pattern to NAA, with significant depletion in the acutely lesioned QA-
striatae, followed by a longer-term recovery. Depletion of striatal TNAA has also been identified in 
rodents with QA lesions (Strauss et al. 1997, Tkac et al. 2001) and in HD patients (van den Bogaard et 
al. 2014, Sturrock et al. 2015) (Jenkins et al. 1993, Clarke et al. 1998, Jenkins et al. 1998, Sturrock et 
al. 2010, van den Bogaard et al. 2011) . Reduction of TNAA can be explained by the significant 




The neuronal loss visible in the QA-lesioned striatae during immunohistochemical examination 
was consistent with the MRS-measured reduction in NAA and TNAA. Necrosis of cellular elements in 
the worst affected region of the epicentre with rarefaction of the neuropil is typical of QA (Beal et al. 
1986, Guncova et al. 2011), while selective sparing of neurons within the heterogenous region of 
neuronal damage is characteristic of changes seen in both QA and HD and has been well described 
(Beal et al. 1986, Beal et al. 1991, Ferrante et al. 1993, Brickell et al. 1999, Ramaswamy et al. 2007). 
The depletion of total creatine seen in the striatae of QA-lesioned sheep and in lesioned rodents 
(Strauss et al. 1997, Tkac et al. 2001) is in keeping with the findings in HD patients (Adanyeguh et al., 
2018; Sanchez-Pernaute, Garcia-Segura, del Barrio Alba, Viano, & de Yebenes, 1999; Sturrock et al., 
2010; van den Bogaard et al., 2014). The changes are likely to reflect impairment of energy 
metabolism, a consequence of both QA-induced excitotoxicity  and HD (Lugo-Huitron et al. 2013). 
The changes in myo-inositol reflect the development of the QA-lesion with initial neuronal loss and 
astrocytic impairment (Ferrante et al. 1993, Feng et al. 2014), followed by the development of 
astrocytosis over time (Brickell et al. 1999). Immunohistochemical examination confirmed 
astrocytosis in the QA-lesioned striatae. Myo-inositol has been reported to be elevated in HD 
patients (Hoang et al. 1998, Jenkins et al. 1998, Sturrock et al. 2010), though one longitudinal study 
found it to decrease (van den Bogaard et al. 2014).  
There is very limited, contradictory information specifically examining the cellular effect of saline 
injections into the brain with both localised, discrete necrosis (Robinson 1969) and neuroprotective 
functions described (Sabel and Stein 1982). The only significant difference in the comparison of 
unlesioned and saline-treated striatae was a decrease in NAA in the chronically lesioned saline-
treated striatae; there was no difference in the acutely-lesioned animals, when saline-mediated 
necrosis would be expected. The reduction in NAA was significantly less profound than that seen in 
the QA-lesioned striatae, consistent with discrete localised cell death with minimal 




of neuronal damage or loss was noted in the saline-treated striatae during immunohistochemical 
examination. 
Neuron death in saline-lesioned striatae was not visible on DTI, suggesting that saline-infusion did 
not result in any significant loss of microstructural tissue integrity. In contrast, the acute drop in grey 
matter FA and disrupted DTI tracts in the QA-lesioned sheep indicate a substantial increase in the 
isotropic freedom of water molecules (Aung et al. 2013) which is consistent with widespread tissue 
disruption and central necrosis (Barbour et al. 1991, Moritani et al. 2005, Lipton 2006, Danbolt et al. 
2016).  
The increase in FA in the striatae of the sheep that have chronic QA lesions is consistent with the 
development of gliosis, as seen during immunohistochemical examination. Gliosis has been shown to 
be a direct cause of increased FA following a brain injury (Budde et al. 2011) while decreased 
freedom of water molecules has been associated with CD68 positive macrophage infiltration in 
rodents with QA-lesioned striatae (Shemesh et al. 2010). However, the significant increase in FA in 
the striatae of chronically-lesioned sheep also potentially reflects structural reorganisation and 
delineation of pathways due to neuronal and axonal sparing (Budde et al. 2011, Harris et al. 2016), 
seen histologically with the preservation of neurons in the penumbra and the sparing of the bundles 
of traversing axons. Neuronal and axonal sparing has also been postulated to be the cause of 
increased FA in the striatum of HD patients (Douaud et al. 2009, Liu et al. 2016).  
5.5 Conclusion 
This study demonstrated the feasibility of using a clinically relevant MR scanner to perform MRS and 
DTI on a translational excitotoxic sheep model of HD as a technique for assessing lesion development 
over time. There has been no longitudinal MRS or DTI examination of the diseased sheep brain 
previously published to our knowledge. Direct comparison with published MRS and DTI studies of 
rodents with QA lesions is difficult because of the differences in the MR scanners used, with small 




Nevertheless, the changes shown in NAA, TNAA, total creatine and FA in the sheep are consistent 
with spectroscopic and DTI changes seen in QA-lesioned rodents, as well as transgenic HD NHPs and 
HD patients, with microstructural change due to neuronal death and gliosis. Immunohistochemical 
examination of the QA-lesioned sheep brain was consistent with the MRS- and DTI- detected 
changes, with a striatal lesion characterised by a central core devoid of neurons surrounded by a 
penumbra with heterogenous gradated neuronal damage and gliosis. The study demonstrates the 
value of using sheep as a large animal model of neurodegenerative disease and illustrates the utility 
of using MRS and DTI at a clinically relevant field strength to examine lesion induced changes in 




















This is the first systematic study of unilateral or bilateral excitotoxic striatal lesions in sheep. 
Lesioning the striatum with the excitotoxin QA is a well-validated HD model in rodents and NHPs 
(Schwarcz and Kohler 1983, Beal et al. 1986, Ferrante et al. 1993, Kendall et al. 2000) that continues 
to be utilised both to model striatal neurodegeneration and investigate therapeutic approaches to 
restoring striatal functionality (Foucault-Fruchard et al. 2018, Sánchez et al. 2018, Sumathi et al. 
2018, Verma et al. 2018, Emerich et al. 2019, Lavisse et al. 2019). Other than NHPs however, no 
excitotoxic large animal model has been developed and assessed, despite the recognised limitations 
of rodent models and the need for relevant comparative animal models to improve translational 
success (Perlman 2016, Whitelaw et al. 2016). In order to lesion the sheep striatum, a stereotactic 
surgical approach was developed and is described in this thesis. 
The development of the striatal lesions in the sheep brain was tracked using non-invasive 
longitudinal MRI. As well as anatomical MR sequences, MRS and DTI were utilised. The author is not 
aware of any other publication that has utilised longitudinal MRS and DTI to study neuropathology of 
the sheep brain. The study generated a unique set of data with over sixty 3-Tesla brain scans from 
sixteen sheep with unilateral and then bilateral striatal lesions. 
A neurological examination specifically aimed at assessing neurological function in sheep is 
described. There is little published data on ruminant neurological examinations (Constable 2004, 
Finnie et al. 2011), and no specific description of a sheep neurological examination. The study also 
describes the assessment of sheep with QA-induced striatal pathology using the sheep neurological 
exam. In particular, the neurological exam was tested for its ability to identify striatal lesions. The 
QA-lesioned sheep appeared normal until interrogated. The neurological examination revealed 
predominantly hindlimb clinical signs that were mild in severity and, interestingly, did not correlate 




A method for quantifying rotation in sheep was developed and used to characterise striatal 
pathology associated with the QA lesions. There has been no previous publication of rotation studies 
performed in sheep with striatal lesions. Information regarding the direction of rotation in QA-
lesioned sheep did not help predict the presence of a striatal lesion. The significant individual 
variation in rotation reduced the usefulness of rotational studies as a technique for assessing striatal 
lesions in sheep. 
The thesis also describes the use of simple two-choice discrimination learning studies in sheep 
with striatal lesions. To the best of the author’s knowledge, there have been no studies published 
describing the cognitive assessment of sheep with excitotoxic lesions of the brain. While the author 
expected the QA-lesioned sheep to be able to acquire the two-choice discrimination, he also 
predicted that the sheep would not be able to perform the reversal. However, the QA-lesioned sheep 
learned both components of the two-choice discrimination learning task. 
6.1 Association between pathology and phenotype 
The variable and mild phenotype in the QA-lesioned sheep may be explained by lesion variation and / 
or brain-repair mechanisms. The considerable inter-animal anatomical variability of sheep skulls and 
the lack of a brain-skull atlas meant that stereotactic placement in the striatum of the study sheep 
was imprecise. This was compounded by the fact that the topography of the striatum is 
heterogeneous with a large number of functional subdivisions (see Section 1.2; Ogawa et al. 2018). 
The phenotypic expression of a lesion may depend on the exact heterogeneous sub-division(s) 
lesioned (Norman et al. 1992, Fricker et al. 1996, Kendall et al. 2000).  
As well as unpredictability of lesion placement, the left and right striatal lesions were performed 
one month apart to avoid adverse animal welfare effects. Brain-repair mechanisms in the first 
striatum to be lesioned may have influenced the functional impact of the second, bilateral, lesion. 
After even a mild brain injury, there is evidence of on-going structural reorganisation, functional 




continuing for at least a year (Kou and Iraji 2014, Dall'Acqua et al. 2017). Brain-repair was evident in 
the QA-lesioned sheep during the four month period after the first surgery when phenotypic studies 
were conducted. During surgical recovery, sheep that were clinically impaired showed a rapid 
improvement, such that they appeared functionally normal within a week of surgery.  
Following acute trauma, there is an initial phase of rapid recovery associated with resolution of 
reversible pathological factors, including oedema related mass effects and uncontrolled 
neuroinflammatory factors (Chen et al. 2010, Marques et al. 2019). Proliferation of glial cells and 
formation of a glial scar moderates the neuroinflammatory response, restores homeostasis and 
creates an environment that promotes brain repair mechanisms including remodelling and plasticity 
(Rolls et al. 2009, Hermann and Chopp 2012). Glial cell hypertrophy is a characteristic of QA striatal 
lesioning (Brickell et al. 1999). Gliosis was evident in vivo in the QA-lesioned sheep in the MR studies 
described in Chapter 5. It was also evident from the immunohistochemical studies.  
The restoration of NAA, a neuron marker (Moffett et al. 2007), over the four month post-surgical 
period, and increases in FA, a diffusion asymmetry index (Aung et al. 2013), reflect recovery of 
reversibly impaired neurons (Shemesh et al. 2010) and structural reorganisation, including 
connectivity changes and delineation of pathways (Douaud et al. 2009, Budde et al. 2011, Harris et al. 
2016, Liu et al. 2016). While the final rotation study provides evidence that at least one lesion is 
creating a functional impact in the QA-lesioned sheep, it likely that variation and repair reduced the 
phenotypic impact of the lesions. 
For major neurodegenerative diseases like HD, at the point at which a disease progresses from 
being asymptomatic to clinically evident, there is already significant neuropathology in the brains of 
patients. At the time of diagnosis, HD patients have significant whole-brain volume loss, ventricle 
expansion and striatal atrophy when compared to control patients (Tabrizi et al. 2012). Despite 
evidence of brain repair in the QA-lesioned sheep, there was still significant pathology evident; in the 




atrophy and in the post mortem brain, immunohistochemistry reveals widespread striatal neuron 
loss and gliosis (Chapter 5). What is interesting is the mismatch between the severity of the 
pathology and the relative paucity of detectable clinical signs in the phenotype studies described in 
Chapters 3 and 4. The QA-lesioned sheep appeared behaviourally to be no different from the saline-
treated sheep. To provoke the mild (albeit variable) phenotype required careful veterinary 
neurological examination performed by experienced veterinarians and pharmacological intervention 
in rotation studies. However, neither technique could reliably identify QA-lesioned sheep.  
Late onset neurodegenerative diseases such as HD that remain asymptomatic despite 
degenerative changes, illustrate the ability of the human brain to compensate for significant 
pathological change. Functionally normal QA-lesioned sheep illustrate the ability of the sheep brain 
to compensate for significant pathology, providing evidence of the value of sheep as a model of 
human neurodegenerative disease. Furthermore, the variability of symptoms of the QA-lesioned 
sheep is consistent both with HD patients as well as NHPs with striatal lesions (Hantraye et al. 1990, 
Burns et al. 1995). Together, these results indicate that sheep are a relevant animal model of HD. 
6.2 Comparison with large animal quinolinic acid models 
Prior to this study, NHPs were the only large animal that has been lesioned with QA to create a 
model of HD. Table 6.1 provides a summary of the various studies that investigated QA-lesioning of 
the NHPs striatum. The total number of animals in each study were very small, ranging from three 
(Brownell et al. 1994) to twelve (Ferrante et al. 1993, Kendall et al. 2000). Lavisse et al. (2019) utilised 
six QA-lesioned NHPs and up to twenty eight unlesioned NHPs in some of their cognitive tests. Eight 
lesioned animals and eight sham-lesion controls were utilised in the present study. Despite animal 
numbers being greater than all but one NHP studies, the behavioural studies described in this thesis 
were still underpowered. The low numbers illustrate the ethical and financial cost of large animal 
studies, plus the difficulty in generating significant study subjects. The majority of the NHP studies 




Burns et al. 1995, Kendall et al. 2000). Four studies had bilateral lesions (Burns et al. 1995, Roitberg 
et al. 2002, Clarke et al. 2008, Lavisse et al. 2019). Roitberg et al (2002) lesioned each striatum four 
weeks apart, a strategy also employed in this study. 
Despite variation in species, study design and exact area targeted, there were findings across the 
NHP studies that were consistent with this study in sheep. In particular, both NHPs and sheep 
appeared functionally normal after the initial surgical recovery period. Motor abnormalities were 
inducible in the lesioned NHPs and sheep using a dopamine agonist, and gross anatomical lesion 
development in the NHPs and sheep was similar, with ventricular dilation and marked central 
neuronal loss and gliosis, surrounded by an area of incomplete neuron loss. The only major 
difference was that, unlike in this study, three NHP studies observed a decline in cognition in QA-
lesioned animals (Roitberg et al. 2002, Clarke et al. 2008, Lavisse et al. 2019), though interestingly 
Lavisse et al (2019) found no significant difference in the simple discrimination reversal task when it 
was performed for the first time at six months post-surgery. The similarities provide support for 
functional parallels between the primate and sheep brain, and suggest that sheep can model 







Table 6.1 Excitotoxic non-human primate models of Huntington’s disease that used quinolinic acid to lesion the striatum 
Species  Model and target Surgical recovery Apomorphine (motor) Cognition Histology / MRI 
Macaca mulatta1  Unilateral.               
CN + P 
Few spontaneous 
abnormal movements 
Dyskinesia  n/a Neuron loss, transitional 
zone, gliosis, ventricular 
dilation, axon sparing 
Macaca mulatta and 
fascicularis2  
Unilateral.                
CN + P 




n/a Neuron loss, gliosis, 
axon sparing.  
Macaca mulatta3  Unilateral.             
Two CN (first) + P. 
Three P only (one 
had bilateral P) 
Unilateral: mild transient 
dyskinesia 1 week. 
Bilateral: marked chorea, 
dyskinesia for 2 days 
CN: no or mild dystonia. 
Others: dystonia, dyskinesia, 
variable rotation 
n/a Lesion visible on MRI 
Callithrix jacchus4  Unilateral.             
Four CN. Four P 
P lesion: dystonia up to 48 
hours. CN lesion: no 
abnormalities detected 
P lesion: ipsilateral rotation, 
dystonia, dyskinesia. CN 
lesion: contralateral rotation 
n/a Neuron loss, gliosis, 
axon sparing, 
ventricular dilation 
Cebus apella5  Bilateral, four 
weeks apart.           
CN + P 
3-5 days of paresis, 
spontaneous rhythmic 
movements, poor feeding, 
seizures 
Exacerbated posture, 
dyskinesia, dystonia, fine 




Neuron loss, transitional 
zone, gliosis, ventricular 
dilation, axon sparing 
Callithrix jacchus6  Bilateral.                  
CN 
Not discussed n/a Could not learn 
reversal task 
Neuron loss, gliosis 
Macaca fascicularis7  Bilateral.                   
CN + P 





Neuron loss, ventricular 
dilation 
1(Ferrante et al. 1993) and (Storey et al. 1994) 2(Brownell et al. 1994) 3(Burns et al. 1995) 4(Kendall et al. 2000) 5(Roitberg et al. 2002) 6(Clarke et al. 2008)  




6.3 Study limitations 
As discussed in the previous section, generating a statistically well-powered sample size when 
conducting behavioural and surgical research studies in large animals is difficult. The present study 
exceeded the sample size of the other QA-lesioned large animal studies while examining motor and 
in vivo anatomical and metabolic changes in the QA-lesioned sheep and only one large animal study 
used more control animals during cognitive testing. The sample size in this study was also larger than 
that utilised in an investigation of the Tay-Sachs sheep model (Gray-Edwards et al. 2018) and larger 
than the sample size in two out of three of the QA-rodent MRS studies (Tkac et al. 2001, Shemesh et 
al. 2010). However, the sample size in the present study is still small in comparison to many rodent 
studies.  
Under-powering of the study was compounded by the variation in the QA lesions, which was 
complicated by an anatomically heterogeneous striatum, though this is highly relevant when 
modelling the human condition. Statistically the behavioural component of the present study was 
under-powered. However, the anatomical MRI, DTI and MRS results were well-powered, consistent 
with the histological findings and often had very small p-values, therefore the author is confident of 
the MR results. The behavioural study data would benefit from greater power due to either larger 
numbers or less variable lesion placement. No relationship was found between lesion size or location 
and behaviour. While this may be a true result or due to the specific tests and methodology used, it 
is likely that more accurate lesioning or greater animal numbers would have allowed differences in 
the outcome of lesions made in different regions of the striatum to be apparent.  
To be truly useful as an excitotoxic model, the sheep needs to be accurately lesioned. The lack of 
a stereotactic skull-brain atlas means that lesioning of the striatum cannot be accurately performed 
at the moment without the assistance of specialist imaging equipment and expertise (van der Bom et 
al. 2013). There are sheep brain atlases available (Ella et al. 2017, Johnson et al. 2019), however they 




diverse, with significant variation within and between populations (Cao et al. 2015, Wang et al. 2017, 
Yang et al. 2018). A uniform cohort of sheep sourced from one location can still show substantial 
variation in the anatomy of their skulls. It is likely that any development of a skull-brain atlas in sheep 
will only be useful for a sub-population of sheep.  
6.3 Future directions 
One area of future experimentation is the testing of QA-lesioned sheep with more refined 
phenotyping procedures. The behavioural tests selected for use in this study were insensitive to 
significant striatal pathology. The ability to test for executive decision making ability in sheep has 
been extended beyond simple two-choice discrimination learning tasks, with sheep demonstrated to 
be capable of more complex decision making tasks, including attentional set shifting (Morton and 
Avanzo 2011, McBride et al. 2016). Future investigation of the decision-making capabilities of QA-
lesioned sheep may reveal cognitive impairment, the caveat being to power the study appropriately.  
Gait and force analysis might also prove to be more sensitive to motor deficits than the veterinary 
neurological examination or rotation studies used in this study. Gait analysis is established in sheep 
(Faria et al. 2014, Mora-Macias et al. 2015, Safayi et al. 2015). The detection of a hind limb motor 
deficits and increased rotation in the QA-lesioned sheep, compared to saline-treated sheep warrants 
further investigation. Gait analysis may detect animals with lesions of the striatum more accurately 
and allow the characterisation of lesions.  
Hyperactivity at night has been detected in QA-lesioned rodents (Shear et al. 1998) and NHPs 
(Roitberg et al. 2002). Sleep disturbances are a common symptom in many neurodegenerative 
diseases (Cipriani et al. 2015, Ramos and Garrett 2017), while circadian rhythm disturbances have 
been detected in the OVT73 transgenic sheep HD model (Morton et al. 2014). An activity monitoring 
study was undertaken in the QA-lesioned sheep (Appendix B), however due to the difficulty of 
conducting the study in conjunction with other behavioural studies and data recording and download 




sheep would provide further information on the capability of sheep to accurately model 
neurodegenerative diseases.  
Finally, the traditional QA-model of HD focuses on lesioning the striatum because of the early and 
severe striatal pathology in HD (Vonsattel et al. 1985). However, pathological change is widespread 
in HD, both within and outside of the brain (Vonsattel et al. 1985). Heterogeneous cerebral cortex 
degeneration is a significant aspect of the HD pathology and resultant phenotype displayed by an 
individual (Thu et al. 2010, Waldvogel et al. 2012b, Kim et al. 2014, Nana et al. 2014) while cerebellar 
degeneration has been associated with the motor phenotype (Singh-Bains et al. 2019). The 
development of cortical pathology when lesioning the striatum with QA is consistent with NHP 
studies (Kendall et al. 2000, Lavisse et al. 2019) and very useful, despite the analytical complication, 
because it more accurately represents HD pathology. Intracerebro-ventricular infusions of QA are a 
well described technique for investigating whole brain excitotoxic effects (Lisy et al. 1994, 
Vandresen-Filho et al. 2015). Assessing the impact of intracerebro-ventricular QA infusions in 
combination with striatal lesions would be a potential way to extend this model and may generate a 
more realistic phenotypic representation.  
6.4 Conclusion 
The QA model of HD continues to be an important model for therapeutic development and studying 
disease mechanisms. NHPs are the gold-standard large animal neurodegenerative model due to their 
neuroanatomical similarity to humans, including a large brain volume and highly developed cerebral 
cortex (Emborg 2017). Clinical trials based only on rodent studies have poorer translational success 
than those that incorporated NHPs studies during pre-clinical progression (Zeiss 2017, Zeiss et al. 
2017). The studies described in this thesis demonstrate that sheep have the potential to be 
important as large animal models of neurodegenerative disease. Sheep have large brains, that are 
neuroanatomically similar to primates, with a highly developed cerebral cortex and good cognitive 




advantages to NHPs, including cost, availability, ethical concern and ease of management. The 
experiments described here demonstrate that lesioning the sheep striatum with QA produces 
neuropathology that is comparable to that seen in QA-lesioned rodents and NHPs. They also show 
that longitudinal characterisation of QA lesions using advanced magnetic resonance modalities and 
phenotypic investigation of the lesioned sheep is possible. Despite its limitations, the QA-lesioned 
sheep represent an authentic animal model of the neurodegenerative condition, HD, that could be 



















7 Appendix A: Method development 
 
This appendix gives a brief overview of the method development process for the methods / studies 
described in the main body of the thesis. There were no applicable protocols for the methods 
undertaken. All methods had to be developed and optimised with a series of pilot studies.  
In brief, initial surgical development was based on cadaver surgeries. Once the basic surgical 
method was developed, ten sheep underwent a total of nineteen surgical procedures to refine the 
surgical process. As well as optimisation of the stereotactic mounting position and surgical 
procedure, the surgical coordinates, concentration and volume of QA infusion and time between left 
and right striatal lesioning was adjusted after each surgery to achieve the optimal surgical method 
described in Chapter 2.  
The first six surgical pilot study sheep were euthanised after recovery from their second surgery. 
Perfusion, brain removal and histological methodology was refined using these sheep. The last four 
surgical pilot study sheep and three non-surgical control sheep were used to develop the behavioural 
study methodologies. 
The neurological examination utilised in Chapter 3 was developed primarily from De Lahunta’s 
detailed canine veterinary neurological examination (de Lahunta and Glass 2009), combined with less 
detailed descriptions of generic (not species specific) large animal neurological examinations and the 
author’s veterinary experience. No sheep specific veterinary neurological examination has been 
published previously. A two person examination was developed because it facilitated handling of the 
sheep as well as improved accuracy. Refinement of the location of the examination and size of the 
pens was very important. Because sheep are naturally flighty, larger pens were found to cause issues 
and potential injuries as sheep would evade handlers and become worked up. The facilities described 





Rotation studies were developed from published rodent studies. Five pilot studies were 
performed with pen shape, size, location and protocol varying. The pens utilised in Chapter 4 were 
the optimum size pen. Circular pens were trialled, but the author was unable to construct a suitably 
robust circular pen. Square or rectangular pens did not appear to inhibit rotation. Pens that were too 
small inhibited rotation while pens that were too large made handling difficult and risked the sheep 
injuring themselves. For the longitudinal studies, it was important that the sheep were under cover 
and in a location that was free from disturbance.  
The development of the discrimination study protocol and apparatus was the most time 
consuming and difficult of the behavioural studies described in the study. As well as fitting within 
existing facilities, the author needed to be able to construct the apparatus from recycled materials 
(due to funding constraints) and operate the discrimination studies without assistance. There were 
many design iterations and pilot trials performed to refine the end facility and protocol described in 
Chapter 4. A low stress environment, good flow and proximity of flockmates were essential. While 
various semi-automatic, computer based systems for symbol and reward presentation were trialled, 
the simple coloured bucket system was easy to use and the sheep understood the protocol faster 
than two dimensional symbols on computer or paper, rendering the coloured buckets the most 
suitable method of symbol presentation in the two-choice discrimination learning protocol. A pulley 










8 Appendix B: Activity monitoring 
 
An activity monitoring study was undertaken on the sixteen sheep used in the main body of the 
thesis. Activity monitoring is a valuable tool for investigation of circadian rhythm abnormalities. 
Disruption of circadian rhythm with alterations in normal sleep and activity periods are clinical 
features of numerous neurodegenerative diseases, including Alzheimer’s (Homolak et al. 2018), 
Parkinson’s (Askenasy 2001) and Huntington’s (Diago et al. 2018) disease.  
Access to a scientifically valid accelerometer device (Actiwatch) used to monitor activity and 
provide circadian behaviour measurements was provided at the beginning of the two-choice 
discrimination learning study (the activity monitors were not available previously). The actiwatch had 
been placed inside a waterproof plastic container containing cotton wool to prevent movement of 
the actiwatch within the container. The plastic container was securely fixed to a large dog collar. The 
dog collar was placed around the neck of the sheep with the plastic container in the ventral position. 
The sheep were unshorn with sufficient wool growth to allow the collar to be tight around the neck, 
preventing artificial movement of the collar without compromising welfare. Epoch length was five 
minutes and recording was programmed to begin twenty four hours after the collar was placed 
around the neck of the sheep to prevent artificial movement recordings and allow a period of time 
for collar adjustments. Sheep were maintained in their group pens during recording. To prevent the 
influence of pen factors on activity, group pens were approximately the same size (eight by five 
metres) with troughs located in the same location within the pens and feed placed in the middle of 
the pens. Shelter was provided by trees planted in line with the border between pens. Actiwatch 
proprietary software was used for actogram construction. Clocklab software was available for 
circadian rhythm analysis.  
Unfortunately, due to hardware and software issues, the data obtained was not of a sufficient 




9 Appendix C: Cerebrospinal fluid analysis 
 
Lipidomic analysis of CSF was also performed. CSF was sampled immediately after MRI 1, MRI 2, MRI 
3 and MRI 4 while the sheep were still anaesthetised. The aim was to try an identify a lipidomic 
marker of QA-induced striatal injury in sheep. Sixty CSF samples were collected, processed and 
analysed. 
9.1.1 Cerebrospinal fluid collection 
Sheep were anaesthetised according to the protocol described in Chapter 2, Section 2.5. CSF 
sampling was based on a standard CSF collection protocol (Scott 2010). Sheep were placed in sternal 
recumbency with the hind limbs projecting forwards to flex the lumbosacral region. A 10 × 10 cm 
area was shaved at the lumbosacral junction and aseptically prepared. Sterile surgical techniques 
were maintained throughout the procedure. The lumbosacral space was palpated as a midline 
depression between the dorsal processes of L6 and S2. A 19-gauge spinal needle was advanced 
perpendicular to the vertebral column, through cutaneous, subcutaneous, ligamentous and dural 
tissue into the subarachnoid space. Appreciation of resistance change during needle travel indicated 
successful location of the subarachnoid space which was confirmed by presence of CSF fluid in the 
needle hub. Gentle aspiration of CSF using a 2 mL syringe was performed to collect 2 – 4 mL of CSF. 
9.1.2 Cerebrospinal fluid processing 
CSF was placed on ice and transferred for immediate processing after collection, with gross 
appearance noted. The CSF sample was agitated for ten seconds to homogenise the CSF and 100 µl 
removed for RBC and WBC quantification using a haemocytometer. CSF was then centrifuged at 
2,000 × g for ten minutes at 4°C to remove cells and gross appearance noted. The supernatant was 
transferred to a 10 mL polypropylene tube on ice and agitated for ten seconds prior to aliquoting into 
pre-chilled polypropylene cryovials (1.2 mL; Corning, NY, USA). Aliquoted samples were snap-frozen 




9.1.3 Lipidomic analysis of cerebrospinal fluid samples 
A –80°C 250 µl aliquot of CSF was thawed, agitated and 200 µl was aliquoted into a centrifuge tube 
(Eppendorf, Hamburg, Germany). 10% Methanol, 800 µl, was added to the centrifuge tube to 
precipitate protein and the CSF centrifuged at 1,300 rpm for ten minutes. Supernatant was pipetted 
into a glass vial and placed in a N2 dryer. Once dry 100 µl 10% methanol was used to resuspend the 
CSF sample, the sample was agitated and 100 µl was pipetted into centrifuge tubes. Resuspended 
CSF samples were centrifuged at 1,300 rpm for ten minutes. Supernatant was pipetted into a 96 well 
plate. A 5 µl sample was removed from each well and placed into a collective vial. 10% Methanol, 
100 µl, was pipetted into the bottow wells of the 96 well plate. The 96 well plate was sealed with foil 
and stored in a 4°C fridge for analysis.  
An Acquity UPLC LC system was used to separate lipids in the CSF sample (Acquity UPLC CSH 
column, C18 2.1 × 100 mm, 1.7 µm, column temperature 55°C, flow rate 400 µl / min, mobile phase A 
acetonitrile / water (60 : 40) with 10 mM ammonium formate and 0.1% formic acid, mobile phase B 
isopropanol / acetonitrile (90 : 10) with 10 mM ammonium formate and 0.1% formic acid, injection 
volume 5 µl). A Xevo G2 XS QToF mass spectrometer was used to detect samples (acquisition mode 
LC/MS, ESI positive ionization mode, capillary voltage 2.0KV, cone voltage 30V, desolvation 
temperature 550°C, desolvation gas 900 L / hr, source temperature 120°C, acquisition range 100 – 
2000 m/z). All ketoacyl subunits were identified for comparison: fatty acyls, glycerolipids 
(monoacylglycerols, diacylglycerols and triacylglycerols), glycerophospholipids (phosphatidylcholines, 
phosphatidylethanolamines, phosphatidylglycerols, phosphatidylserines, phosphatidylinositols and 
cardiolipins) and sphingolipids (ceramides and sphingomyelins). The sterol lipids call of isoprene 
subunits were also identified for comparison: cholesterol and cholesterol esters. Lipid comparisons 
were made using proprietary software. 
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